Δημοσιεύσεις
2019
Konerding, Uwe; Bowen, Tom; Elkhuizen, Sylvia G; Faubel, Raquel; Forte, Paul; Karampli, Eleftheria; Malmström, Tomi; Pavi, Elpida; Torkki, Paulus
Development of a universal short patient satisfaction questionnaire on the basis of SERVQUAL: Psychometric analyses with data of diabetes and stroke patients from six different European countries Journal Article
In: PLoS One, vol. 14, no. 10, pp. e0197924, 2019.
@article{Konerding2019-gy,
title = {Development of a universal short patient satisfaction
questionnaire on the basis of SERVQUAL: Psychometric analyses
with data of diabetes and stroke patients from six different
European countries},
author = {Uwe Konerding and Tom Bowen and Sylvia G Elkhuizen and Raquel Faubel and Paul Forte and Eleftheria Karampli and Tomi Malmström and Elpida Pavi and Paulus Torkki},
year = {2019},
date = {2019-10-01},
journal = {PLoS One},
volume = {14},
number = {10},
pages = {e0197924},
abstract = {OBJECTIVE: A short questionnaire which can be applied for
assessing patient satisfaction in different contexts and
different countries is to be developed. METHODS: Six items
addressing tangibles, reliability, responsiveness, assurance,
empathy, and communication were analysed. The first five items
stem from SERVQUAL (SERVice QUALity), the last stems from the
discussion about SERVQUAL. The analyses were performed with data
from 12 surveys conducted in six different countries (England,
Finland, Germany, Greece, the Netherlands, Spain) covering two
different conditions (type 2 diabetes, stroke). Sample sizes for
included participants are 247 in England, 160 in Finland, 231 in
Germany, 152 in Greece, 316 in the Netherlands and 96 in Spain
for the diabetes surveys; and 101 in England, 139 in Finland, 107
in Germany, 58 in Greece, 185 in the Netherlands, and 92 in Spain
for the stroke surveys. The items were tested by (1) bivariate
correlations between the items and an item addressing 'general
satisfaction', (2) multivariate regression analyses with 'general
satisfaction' as criterion and the items as predictors, and (3)
bivariate correlations between sum scores and 'general
satisfaction'. RESULTS: The correlations with 'general
satisfaction' are 0.48 for tangibles, 0.56 for reliability, 0.58
for responsiveness, 0.47 for assurance, 0.53 for empathy, and
0.56 for communication. In the multivariate regression analysis,
the regression coefficient for assurance is significantly
negative while all other regression coefficients are
significantly positive. In a multivariate regression analysis
without the item 'assurance' all regression coefficients are
positive. The correlation between the sum score and 'general
satisfaction' is 0.608 for all six items and 0.618 for the
finally remaining five items. The country specific results are
similar. CONCLUSIONS: The five items which remain after removing
'assurance', i.e. the SERVQUAL-MOD-5, constitute a short patient
satisfaction index which can usefully be applied for different
medical conditions and in different countries.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVE: A short questionnaire which can be applied for
assessing patient satisfaction in different contexts and
different countries is to be developed. METHODS: Six items
addressing tangibles, reliability, responsiveness, assurance,
empathy, and communication were analysed. The first five items
stem from SERVQUAL (SERVice QUALity), the last stems from the
discussion about SERVQUAL. The analyses were performed with data
from 12 surveys conducted in six different countries (England,
Finland, Germany, Greece, the Netherlands, Spain) covering two
different conditions (type 2 diabetes, stroke). Sample sizes for
included participants are 247 in England, 160 in Finland, 231 in
Germany, 152 in Greece, 316 in the Netherlands and 96 in Spain
for the diabetes surveys; and 101 in England, 139 in Finland, 107
in Germany, 58 in Greece, 185 in the Netherlands, and 92 in Spain
for the stroke surveys. The items were tested by (1) bivariate
correlations between the items and an item addressing 'general
satisfaction', (2) multivariate regression analyses with 'general
satisfaction' as criterion and the items as predictors, and (3)
bivariate correlations between sum scores and 'general
satisfaction'. RESULTS: The correlations with 'general
satisfaction' are 0.48 for tangibles, 0.56 for reliability, 0.58
for responsiveness, 0.47 for assurance, 0.53 for empathy, and
0.56 for communication. In the multivariate regression analysis,
the regression coefficient for assurance is significantly
negative while all other regression coefficients are
significantly positive. In a multivariate regression analysis
without the item 'assurance' all regression coefficients are
positive. The correlation between the sum score and 'general
satisfaction' is 0.608 for all six items and 0.618 for the
finally remaining five items. The country specific results are
similar. CONCLUSIONS: The five items which remain after removing
'assurance', i.e. the SERVQUAL-MOD-5, constitute a short patient
satisfaction index which can usefully be applied for different
medical conditions and in different countries.
assessing patient satisfaction in different contexts and
different countries is to be developed. METHODS: Six items
addressing tangibles, reliability, responsiveness, assurance,
empathy, and communication were analysed. The first five items
stem from SERVQUAL (SERVice QUALity), the last stems from the
discussion about SERVQUAL. The analyses were performed with data
from 12 surveys conducted in six different countries (England,
Finland, Germany, Greece, the Netherlands, Spain) covering two
different conditions (type 2 diabetes, stroke). Sample sizes for
included participants are 247 in England, 160 in Finland, 231 in
Germany, 152 in Greece, 316 in the Netherlands and 96 in Spain
for the diabetes surveys; and 101 in England, 139 in Finland, 107
in Germany, 58 in Greece, 185 in the Netherlands, and 92 in Spain
for the stroke surveys. The items were tested by (1) bivariate
correlations between the items and an item addressing 'general
satisfaction', (2) multivariate regression analyses with 'general
satisfaction' as criterion and the items as predictors, and (3)
bivariate correlations between sum scores and 'general
satisfaction'. RESULTS: The correlations with 'general
satisfaction' are 0.48 for tangibles, 0.56 for reliability, 0.58
for responsiveness, 0.47 for assurance, 0.53 for empathy, and
0.56 for communication. In the multivariate regression analysis,
the regression coefficient for assurance is significantly
negative while all other regression coefficients are
significantly positive. In a multivariate regression analysis
without the item 'assurance' all regression coefficients are
positive. The correlation between the sum score and 'general
satisfaction' is 0.608 for all six items and 0.618 for the
finally remaining five items. The country specific results are
similar. CONCLUSIONS: The five items which remain after removing
'assurance', i.e. the SERVQUAL-MOD-5, constitute a short patient
satisfaction index which can usefully be applied for different
medical conditions and in different countries.
Konerding, Uwe; Bowen, Tom; Elkhuizen, Sylvia G; Faubel, Raquel; Forte, Paul; Karampli, Eleftheria; Malmström, Tomi; Pavi, Elpida; Torkki, Paulus
Development of a universal short patient satisfaction questionnaire on the basis of SERVQUAL: Psychometric analyses with data of diabetes and stroke patients from six different European countries Journal Article
In: PLoS One, vol. 14, no. 10, pp. e0197924, 2019.
@article{Konerding2019-qr,
title = {Development of a universal short patient satisfaction
questionnaire on the basis of SERVQUAL: Psychometric analyses
with data of diabetes and stroke patients from six different
European countries},
author = {Uwe Konerding and Tom Bowen and Sylvia G Elkhuizen and Raquel Faubel and Paul Forte and Eleftheria Karampli and Tomi Malmström and Elpida Pavi and Paulus Torkki},
year = {2019},
date = {2019-10-01},
journal = {PLoS One},
volume = {14},
number = {10},
pages = {e0197924},
abstract = {OBJECTIVE: A short questionnaire which can be applied for
assessing patient satisfaction in different contexts and
different countries is to be developed. METHODS: Six items
addressing tangibles, reliability, responsiveness, assurance,
empathy, and communication were analysed. The first five items
stem from SERVQUAL (SERVice QUALity), the last stems from the
discussion about SERVQUAL. The analyses were performed with data
from 12 surveys conducted in six different countries (England,
Finland, Germany, Greece, the Netherlands, Spain) covering two
different conditions (type 2 diabetes, stroke). Sample sizes for
included participants are 247 in England, 160 in Finland, 231 in
Germany, 152 in Greece, 316 in the Netherlands and 96 in Spain
for the diabetes surveys; and 101 in England, 139 in Finland, 107
in Germany, 58 in Greece, 185 in the Netherlands, and 92 in Spain
for the stroke surveys. The items were tested by (1) bivariate
correlations between the items and an item addressing 'general
satisfaction', (2) multivariate regression analyses with 'general
satisfaction' as criterion and the items as predictors, and (3)
bivariate correlations between sum scores and 'general
satisfaction'. RESULTS: The correlations with 'general
satisfaction' are 0.48 for tangibles, 0.56 for reliability, 0.58
for responsiveness, 0.47 for assurance, 0.53 for empathy, and
0.56 for communication. In the multivariate regression analysis,
the regression coefficient for assurance is significantly
negative while all other regression coefficients are
significantly positive. In a multivariate regression analysis
without the item 'assurance' all regression coefficients are
positive. The correlation between the sum score and 'general
satisfaction' is 0.608 for all six items and 0.618 for the
finally remaining five items. The country specific results are
similar. CONCLUSIONS: The five items which remain after removing
'assurance', i.e. the SERVQUAL-MOD-5, constitute a short patient
satisfaction index which can usefully be applied for different
medical conditions and in different countries.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVE: A short questionnaire which can be applied for
assessing patient satisfaction in different contexts and
different countries is to be developed. METHODS: Six items
addressing tangibles, reliability, responsiveness, assurance,
empathy, and communication were analysed. The first five items
stem from SERVQUAL (SERVice QUALity), the last stems from the
discussion about SERVQUAL. The analyses were performed with data
from 12 surveys conducted in six different countries (England,
Finland, Germany, Greece, the Netherlands, Spain) covering two
different conditions (type 2 diabetes, stroke). Sample sizes for
included participants are 247 in England, 160 in Finland, 231 in
Germany, 152 in Greece, 316 in the Netherlands and 96 in Spain
for the diabetes surveys; and 101 in England, 139 in Finland, 107
in Germany, 58 in Greece, 185 in the Netherlands, and 92 in Spain
for the stroke surveys. The items were tested by (1) bivariate
correlations between the items and an item addressing 'general
satisfaction', (2) multivariate regression analyses with 'general
satisfaction' as criterion and the items as predictors, and (3)
bivariate correlations between sum scores and 'general
satisfaction'. RESULTS: The correlations with 'general
satisfaction' are 0.48 for tangibles, 0.56 for reliability, 0.58
for responsiveness, 0.47 for assurance, 0.53 for empathy, and
0.56 for communication. In the multivariate regression analysis,
the regression coefficient for assurance is significantly
negative while all other regression coefficients are
significantly positive. In a multivariate regression analysis
without the item 'assurance' all regression coefficients are
positive. The correlation between the sum score and 'general
satisfaction' is 0.608 for all six items and 0.618 for the
finally remaining five items. The country specific results are
similar. CONCLUSIONS: The five items which remain after removing
'assurance', i.e. the SERVQUAL-MOD-5, constitute a short patient
satisfaction index which can usefully be applied for different
medical conditions and in different countries.
assessing patient satisfaction in different contexts and
different countries is to be developed. METHODS: Six items
addressing tangibles, reliability, responsiveness, assurance,
empathy, and communication were analysed. The first five items
stem from SERVQUAL (SERVice QUALity), the last stems from the
discussion about SERVQUAL. The analyses were performed with data
from 12 surveys conducted in six different countries (England,
Finland, Germany, Greece, the Netherlands, Spain) covering two
different conditions (type 2 diabetes, stroke). Sample sizes for
included participants are 247 in England, 160 in Finland, 231 in
Germany, 152 in Greece, 316 in the Netherlands and 96 in Spain
for the diabetes surveys; and 101 in England, 139 in Finland, 107
in Germany, 58 in Greece, 185 in the Netherlands, and 92 in Spain
for the stroke surveys. The items were tested by (1) bivariate
correlations between the items and an item addressing 'general
satisfaction', (2) multivariate regression analyses with 'general
satisfaction' as criterion and the items as predictors, and (3)
bivariate correlations between sum scores and 'general
satisfaction'. RESULTS: The correlations with 'general
satisfaction' are 0.48 for tangibles, 0.56 for reliability, 0.58
for responsiveness, 0.47 for assurance, 0.53 for empathy, and
0.56 for communication. In the multivariate regression analysis,
the regression coefficient for assurance is significantly
negative while all other regression coefficients are
significantly positive. In a multivariate regression analysis
without the item 'assurance' all regression coefficients are
positive. The correlation between the sum score and 'general
satisfaction' is 0.608 for all six items and 0.618 for the
finally remaining five items. The country specific results are
similar. CONCLUSIONS: The five items which remain after removing
'assurance', i.e. the SERVQUAL-MOD-5, constitute a short patient
satisfaction index which can usefully be applied for different
medical conditions and in different countries.
Petrakis, Ioannis; Kontogiorgis, Christos; Nena, Evangelia; Athanasakis, Kostas; Gougoula, Vasiliki; Kotsianidis, Ioannis; Constantinidis, Theodoros C
Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma Journal Article
In: Expert Rev Hematol, vol. 12, no. 12, pp. 1063–1075, 2019.
Abstract | BibTeX | Ετικέτες: Hematological malignancies; leukemia; lymphoma; myeloma; real-world evidence
@article{Petrakis2019-uw,
title = {Unraveling innovation potential in the real-world setting:
eighteen novel agents with twenty-six approved European
indications, in the management of leukemias, lymphomas, and
multiple myeloma},
author = {Ioannis Petrakis and Christos Kontogiorgis and Evangelia Nena and Kostas Athanasakis and Vasiliki Gougoula and Ioannis Kotsianidis and Theodoros C Constantinidis},
year = {2019},
date = {2019-09-01},
journal = {Expert Rev Hematol},
volume = {12},
number = {12},
pages = {1063--1075},
address = {England},
abstract = {Introduction: Real-world effectiveness of hemato-oncology
pharmaceuticals may not necessarily mimic clinical trial efficacy
results, mainly due to demographic and clinical practice
variability. The aim of this review was to systematically assess
the availability of real-world evidence (RWE) and the
transferability of clinical trial (CT) efficacy results to real
life, for novel agents recently approved to manage lymphomas,
leukemias, and multiple myeloma. This is the largest
cross-indication review comparing RWE to CT results, aspiring to
inform clinical practice and decision-making when funding
hemato-oncology pharmaceuticals.Areas covered: The review
methodology focused on identifying all novel agents that entered
EU landscape between 2012 and 2016 by using European Medicines
Agency (EMA) database, while conducting a systematic PubMed
literature review of RWE in the specific hematological
malignancies, in order to compare RWE versus CT efficacy
endpoints.Expert opinion: In total, 18 international
nonproprietary names (INNs) that received EMA approval for any
indication were included and the registrational efficacy results
are presented. Eight (44%) INNs proved to have relevant RWE
generated in at least one approved indication. The analysis of
findings revealed high variability in terms of RWE availability
and transferability of CT results to relevant real-life
experience among the disease areas investigated.},
keywords = {Hematological malignancies; leukemia; lymphoma; myeloma; real-world evidence},
pubstate = {published},
tppubtype = {article}
}
Introduction: Real-world effectiveness of hemato-oncology
pharmaceuticals may not necessarily mimic clinical trial efficacy
results, mainly due to demographic and clinical practice
variability. The aim of this review was to systematically assess
the availability of real-world evidence (RWE) and the
transferability of clinical trial (CT) efficacy results to real
life, for novel agents recently approved to manage lymphomas,
leukemias, and multiple myeloma. This is the largest
cross-indication review comparing RWE to CT results, aspiring to
inform clinical practice and decision-making when funding
hemato-oncology pharmaceuticals.Areas covered: The review
methodology focused on identifying all novel agents that entered
EU landscape between 2012 and 2016 by using European Medicines
Agency (EMA) database, while conducting a systematic PubMed
literature review of RWE in the specific hematological
malignancies, in order to compare RWE versus CT efficacy
endpoints.Expert opinion: In total, 18 international
nonproprietary names (INNs) that received EMA approval for any
indication were included and the registrational efficacy results
are presented. Eight (44%) INNs proved to have relevant RWE
generated in at least one approved indication. The analysis of
findings revealed high variability in terms of RWE availability
and transferability of CT results to relevant real-life
experience among the disease areas investigated.
pharmaceuticals may not necessarily mimic clinical trial efficacy
results, mainly due to demographic and clinical practice
variability. The aim of this review was to systematically assess
the availability of real-world evidence (RWE) and the
transferability of clinical trial (CT) efficacy results to real
life, for novel agents recently approved to manage lymphomas,
leukemias, and multiple myeloma. This is the largest
cross-indication review comparing RWE to CT results, aspiring to
inform clinical practice and decision-making when funding
hemato-oncology pharmaceuticals.Areas covered: The review
methodology focused on identifying all novel agents that entered
EU landscape between 2012 and 2016 by using European Medicines
Agency (EMA) database, while conducting a systematic PubMed
literature review of RWE in the specific hematological
malignancies, in order to compare RWE versus CT efficacy
endpoints.Expert opinion: In total, 18 international
nonproprietary names (INNs) that received EMA approval for any
indication were included and the registrational efficacy results
are presented. Eight (44%) INNs proved to have relevant RWE
generated in at least one approved indication. The analysis of
findings revealed high variability in terms of RWE availability
and transferability of CT results to relevant real-life
experience among the disease areas investigated.
Gountas, Ilias; Sypsa, Vana; Papatheodoridis, George; Souliotis, Kyriakos; Athanasakis, Kostas; Razavi, Homie; Hatzakis, Angelos
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals Journal Article
In: World J Gastroenterol, vol. 25, no. 11, pp. 1327–1340, 2019.
Abstract | BibTeX | Ετικέτες: Awareness and screening programs; Cost effectiveness; Cost of elimination; Hepatitis C elimination; Indirect costs; Mathematical modelling; Projections; World Health Organization targets
@article{Gountas2019-ee,
title = {Economic evaluation of the hepatitis C elimination strategy in
Greece in the era of affordable direct-acting antivirals},
author = {Ilias Gountas and Vana Sypsa and George Papatheodoridis and Kyriakos Souliotis and Kostas Athanasakis and Homie Razavi and Angelos Hatzakis},
year = {2019},
date = {2019-03-01},
journal = {World J Gastroenterol},
volume = {25},
number = {11},
pages = {1327--1340},
abstract = {BACKGROUND: Hepatitis C virus (HCV) is a leading cause of
worldwide liver-related morbidity and mortality. The World Health
Organization released an integrated strategy targeting
HCV-elimination by 2030. This study aims to estimate the required
interventions to achieve elimination using updated information
for direct-acting antiviral (DAA) treatment coverage, to compute
the total costs (including indirect/societal costs) of the
strategy and to identify whether the elimination strategy is
cost-effective/cost-saving in Greece. AIM: To estimate the
required interventions and subsequent costs to achieve HCV
elimination in Greece. METHODS: A previously validated
mathematical model was adapted to the Greek HCV-infected
population to compare the outcomes of DAA treatment without the
additional implementation of awareness or screening campaigns
versus an HCV elimination strategy, which includes a sufficient
number of treated patients. We estimated the total costs (direct
and indirect costs), the disability-adjusted life years and the
incremental cost-effectiveness ratio using two different price
scenarios. RESULTS: Without the implementation of awareness or
screening campaigns, approximately 20000 patients would be
diagnosed and treated with DAAs by 2030. This strategy would
result in a 19.6% increase in HCV-related mortality in 2030
compared to 2015. To achieve the elimination goal, 90000 patients
need to be treated by 2030. Under the elimination scenario,
viremic cases would decrease by 78.8% in 2030 compared to 2015.
The cumulative direct costs to eliminate the disease would range
from 2.1-2.3 billion euros (€) by 2030, while the indirect costs
would be €1.1 billion. The total elimination cost in Greece would
range from €3.2-3.4 billion by 2030. The cost per averted
disability-adjusted life year is estimated between €10100 and
€13380, indicating that the elimination strategy is very
cost-effective. Furthermore, HCV elimination strategy would save
€560-895 million by 2035. CONCLUSION: Without large screening
programs, elimination of HCV cannot be achieved. The HCV
elimination strategy is feasible and cost-saving despite the
uncertainty of the future cost of DAAs in Greece.},
keywords = {Awareness and screening programs; Cost effectiveness; Cost of elimination; Hepatitis C elimination; Indirect costs; Mathematical modelling; Projections; World Health Organization targets},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Hepatitis C virus (HCV) is a leading cause of
worldwide liver-related morbidity and mortality. The World Health
Organization released an integrated strategy targeting
HCV-elimination by 2030. This study aims to estimate the required
interventions to achieve elimination using updated information
for direct-acting antiviral (DAA) treatment coverage, to compute
the total costs (including indirect/societal costs) of the
strategy and to identify whether the elimination strategy is
cost-effective/cost-saving in Greece. AIM: To estimate the
required interventions and subsequent costs to achieve HCV
elimination in Greece. METHODS: A previously validated
mathematical model was adapted to the Greek HCV-infected
population to compare the outcomes of DAA treatment without the
additional implementation of awareness or screening campaigns
versus an HCV elimination strategy, which includes a sufficient
number of treated patients. We estimated the total costs (direct
and indirect costs), the disability-adjusted life years and the
incremental cost-effectiveness ratio using two different price
scenarios. RESULTS: Without the implementation of awareness or
screening campaigns, approximately 20000 patients would be
diagnosed and treated with DAAs by 2030. This strategy would
result in a 19.6% increase in HCV-related mortality in 2030
compared to 2015. To achieve the elimination goal, 90000 patients
need to be treated by 2030. Under the elimination scenario,
viremic cases would decrease by 78.8% in 2030 compared to 2015.
The cumulative direct costs to eliminate the disease would range
from 2.1-2.3 billion euros (€) by 2030, while the indirect costs
would be €1.1 billion. The total elimination cost in Greece would
range from €3.2-3.4 billion by 2030. The cost per averted
disability-adjusted life year is estimated between €10100 and
€13380, indicating that the elimination strategy is very
cost-effective. Furthermore, HCV elimination strategy would save
€560-895 million by 2035. CONCLUSION: Without large screening
programs, elimination of HCV cannot be achieved. The HCV
elimination strategy is feasible and cost-saving despite the
uncertainty of the future cost of DAAs in Greece.
worldwide liver-related morbidity and mortality. The World Health
Organization released an integrated strategy targeting
HCV-elimination by 2030. This study aims to estimate the required
interventions to achieve elimination using updated information
for direct-acting antiviral (DAA) treatment coverage, to compute
the total costs (including indirect/societal costs) of the
strategy and to identify whether the elimination strategy is
cost-effective/cost-saving in Greece. AIM: To estimate the
required interventions and subsequent costs to achieve HCV
elimination in Greece. METHODS: A previously validated
mathematical model was adapted to the Greek HCV-infected
population to compare the outcomes of DAA treatment without the
additional implementation of awareness or screening campaigns
versus an HCV elimination strategy, which includes a sufficient
number of treated patients. We estimated the total costs (direct
and indirect costs), the disability-adjusted life years and the
incremental cost-effectiveness ratio using two different price
scenarios. RESULTS: Without the implementation of awareness or
screening campaigns, approximately 20000 patients would be
diagnosed and treated with DAAs by 2030. This strategy would
result in a 19.6% increase in HCV-related mortality in 2030
compared to 2015. To achieve the elimination goal, 90000 patients
need to be treated by 2030. Under the elimination scenario,
viremic cases would decrease by 78.8% in 2030 compared to 2015.
The cumulative direct costs to eliminate the disease would range
from 2.1-2.3 billion euros (€) by 2030, while the indirect costs
would be €1.1 billion. The total elimination cost in Greece would
range from €3.2-3.4 billion by 2030. The cost per averted
disability-adjusted life year is estimated between €10100 and
€13380, indicating that the elimination strategy is very
cost-effective. Furthermore, HCV elimination strategy would save
€560-895 million by 2035. CONCLUSION: Without large screening
programs, elimination of HCV cannot be achieved. The HCV
elimination strategy is feasible and cost-saving despite the
uncertainty of the future cost of DAAs in Greece.
Tentolouris, Anastasios; Eleftheriadou, Ioanna; Tzeravini, Evangelia; Athanasakis, Kostas; Anastasiou, Ioanna A; Kyriopoulos, John; Tentolouris, Nikolaos
Management of diabetes mellitus and patients' attitude towards the disease: Data from a nationwide study in Greece Journal Article
In: Diabetes Metab Syndr, vol. 13, no. 2, pp. 1159–1164, 2019.
Abstract | BibTeX | Ετικέτες: Attitude; Diabetes mellitus; Greece; Insulin concerns; Management; Prevalence; Self-monitoring of blood glucose; Treatment patterns
@article{Tentolouris2019-er,
title = {Management of diabetes mellitus and patients' attitude towards
the disease: Data from a nationwide study in Greece},
author = {Anastasios Tentolouris and Ioanna Eleftheriadou and Evangelia Tzeravini and Kostas Athanasakis and Ioanna A Anastasiou and John Kyriopoulos and Nikolaos Tentolouris},
year = {2019},
date = {2019-01-01},
journal = {Diabetes Metab Syndr},
volume = {13},
number = {2},
pages = {1159--1164},
address = {Netherlands},
abstract = {AIM: To examine management of diabetes mellitus (DM) and
patients' attitude towards DM in a random sample of the adult
Greek population. METHODS: s: We selected a random sample of adults with self-reported DM (n = 1002) from a population-based
nationwide study using the effective random sampling technique.
Collection of data was performed through phone interviews.
RESULTS: Prevalence of type 1 DM was 3.5% and of type 2 DM
96.5%. Prevalence of type 1 DM declined while of type 2 DM
increased with age. No gender or residency differences were found
between type 1 and type 2 DM. A total of 72.0% of subjects with
type 2 DM were treated with oral antidiabetic drugs (OAD), 11.5%
were treated with insulin and 7.1% were treated with both OAD
and insulin. Internists specialized in DM were mainly doctors who
started insulin treatment. Almost half of insulin naive subjects
were skeptical towards insulin initiation and their main concern
was the needle punch. CONCLUSIONS: In a random nationwide sample
of the adult population in Greece the majority of subjects with
self-reported DM had type 2 DM. Most patients with type 2 were
treated with OAD. Almost half of insulin naive subjects were
skeptical towards insulin initiation.},
keywords = {Attitude; Diabetes mellitus; Greece; Insulin concerns; Management; Prevalence; Self-monitoring of blood glucose; Treatment patterns},
pubstate = {published},
tppubtype = {article}
}
AIM: To examine management of diabetes mellitus (DM) and
patients' attitude towards DM in a random sample of the adult
Greek population. METHODS: s: We selected a random sample of adults with self-reported DM (n = 1002) from a population-based
nationwide study using the effective random sampling technique.
Collection of data was performed through phone interviews.
RESULTS: Prevalence of type 1 DM was 3.5% and of type 2 DM
96.5%. Prevalence of type 1 DM declined while of type 2 DM
increased with age. No gender or residency differences were found
between type 1 and type 2 DM. A total of 72.0% of subjects with
type 2 DM were treated with oral antidiabetic drugs (OAD), 11.5%
were treated with insulin and 7.1% were treated with both OAD
and insulin. Internists specialized in DM were mainly doctors who
started insulin treatment. Almost half of insulin naive subjects
were skeptical towards insulin initiation and their main concern
was the needle punch. CONCLUSIONS: In a random nationwide sample
of the adult population in Greece the majority of subjects with
self-reported DM had type 2 DM. Most patients with type 2 were
treated with OAD. Almost half of insulin naive subjects were
skeptical towards insulin initiation.
patients' attitude towards DM in a random sample of the adult
Greek population. METHODS: s: We selected a random sample of adults with self-reported DM (n = 1002) from a population-based
nationwide study using the effective random sampling technique.
Collection of data was performed through phone interviews.
RESULTS: Prevalence of type 1 DM was 3.5% and of type 2 DM
96.5%. Prevalence of type 1 DM declined while of type 2 DM
increased with age. No gender or residency differences were found
between type 1 and type 2 DM. A total of 72.0% of subjects with
type 2 DM were treated with oral antidiabetic drugs (OAD), 11.5%
were treated with insulin and 7.1% were treated with both OAD
and insulin. Internists specialized in DM were mainly doctors who
started insulin treatment. Almost half of insulin naive subjects
were skeptical towards insulin initiation and their main concern
was the needle punch. CONCLUSIONS: In a random nationwide sample
of the adult population in Greece the majority of subjects with
self-reported DM had type 2 DM. Most patients with type 2 were
treated with OAD. Almost half of insulin naive subjects were
skeptical towards insulin initiation.
2018
Konerding, Uwe; Bowen, Tom; Forte, Paul; Karampli, Eleftheria; Malmström, Tomi; Pavi, Elpida; Torkki, Paulus; Graessel, Elmar
Do Caregiver Characteristics Affect Caregiver Burden Differently in Different Countries? Journal Article
In: Am J Alzheimers Dis Other Demen, vol. 34, no. 3, pp. 148–152, 2018.
Abstract | BibTeX | Ετικέτες: caregiver burden; cross-cultural; cross-national; dementia; informal care; informal caregivers
@article{Konerding2018-ie,
title = {Do Caregiver Characteristics Affect Caregiver Burden Differently
in Different Countries?},
author = {Uwe Konerding and Tom Bowen and Paul Forte and Eleftheria Karampli and Tomi Malmström and Elpida Pavi and Paulus Torkki and Elmar Graessel},
year = {2018},
date = {2018-12-01},
journal = {Am J Alzheimers Dis Other Demen},
volume = {34},
number = {3},
pages = {148--152},
address = {United States},
abstract = {The relationships between caregiver burden as measured with the
Burden Scale for Family Caregivers-short form and 6
characteristics of caregivers caring for patients with dementia were investigated for caregivers from England (n = 36), Finland (n = 42), and Greece (n = 46) using survey data. In all 3
countries, caregiver burden increases with physical problems of
the caregiver, emotional problems of the caregiver, and weekly
hours of care. Hence, in all 3 countries, special support for
informal care is required when these characteristics are at high
levels. When the caregiver is a spouse or long-term partner of
the person with dementia, lives in the same house as this person,
or spends fewer than 20 h/wk for other duties than care, this is
associated with less caregiver burden in England but with more
caregiver burden in Greece. Accordingly, special support is
required for Greek caregivers with these characteristics, but the
opposite is true for English caregivers.},
keywords = {caregiver burden; cross-cultural; cross-national; dementia; informal care; informal caregivers},
pubstate = {published},
tppubtype = {article}
}
The relationships between caregiver burden as measured with the
Burden Scale for Family Caregivers-short form and 6
characteristics of caregivers caring for patients with dementia were investigated for caregivers from England (n = 36), Finland (n = 42), and Greece (n = 46) using survey data. In all 3
countries, caregiver burden increases with physical problems of
the caregiver, emotional problems of the caregiver, and weekly
hours of care. Hence, in all 3 countries, special support for
informal care is required when these characteristics are at high
levels. When the caregiver is a spouse or long-term partner of
the person with dementia, lives in the same house as this person,
or spends fewer than 20 h/wk for other duties than care, this is
associated with less caregiver burden in England but with more
caregiver burden in Greece. Accordingly, special support is
required for Greek caregivers with these characteristics, but the
opposite is true for English caregivers.
Burden Scale for Family Caregivers-short form and 6
characteristics of caregivers caring for patients with dementia were investigated for caregivers from England (n = 36), Finland (n = 42), and Greece (n = 46) using survey data. In all 3
countries, caregiver burden increases with physical problems of
the caregiver, emotional problems of the caregiver, and weekly
hours of care. Hence, in all 3 countries, special support for
informal care is required when these characteristics are at high
levels. When the caregiver is a spouse or long-term partner of
the person with dementia, lives in the same house as this person,
or spends fewer than 20 h/wk for other duties than care, this is
associated with less caregiver burden in England but with more
caregiver burden in Greece. Accordingly, special support is
required for Greek caregivers with these characteristics, but the
opposite is true for English caregivers.
Kostaras, Dimitris; Karampli, Eleftheria; Athanasakis, Kostas
Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries Journal Article
In: Expert Rev Pharmacoecon Outcomes Res, vol. 19, no. 2, pp. 147–158, 2018.
Abstract | BibTeX | Ετικέτες: HPV prevention; cost-effectiveness; cost-utility; human papillomavirus; vaccination; vaccines
@article{Kostaras2018-lk,
title = {Vaccination against HPV virus: a systematic review of economic
evaluation studies for developed countries},
author = {Dimitris Kostaras and Eleftheria Karampli and Kostas Athanasakis},
year = {2018},
date = {2018-12-01},
journal = {Expert Rev Pharmacoecon Outcomes Res},
volume = {19},
number = {2},
pages = {147--158},
address = {England},
abstract = {INTRODUCTION: During the last years, a significant number
economic evaluations of HPV vaccination has been published. Given
that cost-effectiveness constitutes an essential part of
decision-making with regards to the reimbursement of a health
technology, the purpose of this study is to provide a supportive
tool to decision-makers regarding the economic efficiency of the
introduction of HPV vaccination to national immunization
programs. AREAS COVERED: The PubMed database was searched in
order to identify cost-effectiveness studies for HPV vaccination.
A total of 42 articles were finally retrieved. All retrieved
cost-effectiveness ratios (ICERs) were converted in the same
currency unit (I$) and then inflated to the same year (2015) in
order to facilitate cross-country comparisons. RESULTS: Overall,
vaccination against HPV 6,11,16,18 types appears to have a ICER
with mean value of I$25132/QALY, whereas the mean ICER of
vaccination against oncogenic HPV 16,18 types is estimated at
I$38,253/QALY. EXPERT COMMENTARY: HPV vaccination would be a
cost-effective intervention in the setting of high-income
countries and could reduce the incidence of HPV-related diseases.},
keywords = {HPV prevention; cost-effectiveness; cost-utility; human papillomavirus; vaccination; vaccines},
pubstate = {published},
tppubtype = {article}
}
INTRODUCTION: During the last years, a significant number
economic evaluations of HPV vaccination has been published. Given
that cost-effectiveness constitutes an essential part of
decision-making with regards to the reimbursement of a health
technology, the purpose of this study is to provide a supportive
tool to decision-makers regarding the economic efficiency of the
introduction of HPV vaccination to national immunization
programs. AREAS COVERED: The PubMed database was searched in
order to identify cost-effectiveness studies for HPV vaccination.
A total of 42 articles were finally retrieved. All retrieved
cost-effectiveness ratios (ICERs) were converted in the same
currency unit (I$) and then inflated to the same year (2015) in
order to facilitate cross-country comparisons. RESULTS: Overall,
vaccination against HPV 6,11,16,18 types appears to have a ICER
with mean value of I$25132/QALY, whereas the mean ICER of
vaccination against oncogenic HPV 16,18 types is estimated at
I$38,253/QALY. EXPERT COMMENTARY: HPV vaccination would be a
cost-effective intervention in the setting of high-income
countries and could reduce the incidence of HPV-related diseases.
economic evaluations of HPV vaccination has been published. Given
that cost-effectiveness constitutes an essential part of
decision-making with regards to the reimbursement of a health
technology, the purpose of this study is to provide a supportive
tool to decision-makers regarding the economic efficiency of the
introduction of HPV vaccination to national immunization
programs. AREAS COVERED: The PubMed database was searched in
order to identify cost-effectiveness studies for HPV vaccination.
A total of 42 articles were finally retrieved. All retrieved
cost-effectiveness ratios (ICERs) were converted in the same
currency unit (I$) and then inflated to the same year (2015) in
order to facilitate cross-country comparisons. RESULTS: Overall,
vaccination against HPV 6,11,16,18 types appears to have a ICER
with mean value of I$25132/QALY, whereas the mean ICER of
vaccination against oncogenic HPV 16,18 types is estimated at
I$38,253/QALY. EXPERT COMMENTARY: HPV vaccination would be a
cost-effective intervention in the setting of high-income
countries and could reduce the incidence of HPV-related diseases.
Tsironis, Georgiops; Koutsoukos, Konstantinos; Athanasakis, Kostas; Tsiara, Anna; Tzannis, Kimon; Gerolympou, Margarita; Visvikis, Anastasios; Oikonomopoulos, Georgios; Kollia, Alexandra; Giannopoulou, Efstathia; Dimitra, Marialena; Kostouros, Efthymios; Papatsoris, Athanasios; Dellis, Athanasios; Stravodimos, Konstantinos; Varkarakis, Ioannis; Samantas, Epaminontas; Aravantinos, Gerasimos; Kentepozidis, Nikolaos; Christodoulou, Christos; Bozionelou, Vasiliki; Dimopoulos, Meletios Athanasios; Bamias, Aristotle
Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG) Journal Article
In: Expert Rev Pharmacoecon Outcomes Res, vol. 19, no. 4, pp. 491–501, 2018.
Abstract | BibTeX | Ετικέτες: Greece; Hellenic Genitourinary Cancer Group-HGUCG; metastatic RCC; pharmacoeconomic analysis; targeted therapy
@article{Tsironis2018-vn,
title = {Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)},
author = {Georgiops Tsironis and Konstantinos Koutsoukos and Kostas Athanasakis and Anna Tsiara and Kimon Tzannis and Margarita Gerolympou and Anastasios Visvikis and Georgios Oikonomopoulos and Alexandra Kollia and Efstathia Giannopoulou and Marialena Dimitra and Efthymios Kostouros and Athanasios Papatsoris and Athanasios Dellis and Konstantinos Stravodimos and Ioannis Varkarakis and Epaminontas Samantas and Gerasimos Aravantinos and Nikolaos Kentepozidis and Christos Christodoulou and Vasiliki Bozionelou and Meletios Athanasios Dimopoulos and Aristotle Bamias},
year = {2018},
date = {2018-11-01},
urldate = {2018-11-01},
journal = {Expert Rev Pharmacoecon Outcomes Res},
volume = {19},
number = {4},
pages = {491--501},
address = {England},
abstract = {Background:Metastatic RCC (mRCC) treatment has been
revolutionized with 11 approved targeted agents. We report
patterns of practice, outcomes and pharmacoeconomic analyses
after the introduction of targeted therapy. Patients and methods:
CRISIS was a retrospective multicenter study of mRCCpatients who
received targeted therapy . Results were related to the start of
1st-line therapy, with a cut off at 1 January 2011 in order to
depict the impact of increased availability of effective options.
Results: 164 patients, were included. 70.1% and 44.5% received
2nd and 3rd-line therapy, respectively. More patients were
treated in 2nd-line after 1 January 2011. After a median
follow-up of 55.1 months, median progression-free (PFS) and
overall survival (OS) were 10.7 (95% confidence intervals [CI]:
8.3-13.7), 7.3 (95% CI: 5.1-8.6), 5.8 (95% CI: 3.8-7.8) and 34
(95% CI: 28.5-39.8), 22.4 (95% CI: 16-32.1), 18.3 (95% CI:
12.4-26.4) months for first, second and third line, respectively.
Efficacy of sunitinib and pazopanib in 1st-line were similar. The
mean total cost/patient was 35,012.2 Euros (standard deviation
[SD]: 28,971.5). Conclusions: Our study confirms previous
real-world data suggesting that continuing advances in the
treatment of mRCC produce favorable outcomes in everyday
practice. Pharmacoeconomic analyses are important for
cost-effective utilization of emerging novel therapies.},
keywords = {Greece; Hellenic Genitourinary Cancer Group-HGUCG; metastatic RCC; pharmacoeconomic analysis; targeted therapy},
pubstate = {published},
tppubtype = {article}
}
Background:Metastatic RCC (mRCC) treatment has been
revolutionized with 11 approved targeted agents. We report
patterns of practice, outcomes and pharmacoeconomic analyses
after the introduction of targeted therapy. Patients and methods:
CRISIS was a retrospective multicenter study of mRCCpatients who
received targeted therapy . Results were related to the start of
1st-line therapy, with a cut off at 1 January 2011 in order to
depict the impact of increased availability of effective options.
Results: 164 patients, were included. 70.1% and 44.5% received
2nd and 3rd-line therapy, respectively. More patients were
treated in 2nd-line after 1 January 2011. After a median
follow-up of 55.1 months, median progression-free (PFS) and
overall survival (OS) were 10.7 (95% confidence intervals [CI]:
8.3-13.7), 7.3 (95% CI: 5.1-8.6), 5.8 (95% CI: 3.8-7.8) and 34
(95% CI: 28.5-39.8), 22.4 (95% CI: 16-32.1), 18.3 (95% CI:
12.4-26.4) months for first, second and third line, respectively.
Efficacy of sunitinib and pazopanib in 1st-line were similar. The
mean total cost/patient was 35,012.2 Euros (standard deviation
[SD]: 28,971.5). Conclusions: Our study confirms previous
real-world data suggesting that continuing advances in the
treatment of mRCC produce favorable outcomes in everyday
practice. Pharmacoeconomic analyses are important for
cost-effective utilization of emerging novel therapies.
revolutionized with 11 approved targeted agents. We report
patterns of practice, outcomes and pharmacoeconomic analyses
after the introduction of targeted therapy. Patients and methods:
CRISIS was a retrospective multicenter study of mRCCpatients who
received targeted therapy . Results were related to the start of
1st-line therapy, with a cut off at 1 January 2011 in order to
depict the impact of increased availability of effective options.
Results: 164 patients, were included. 70.1% and 44.5% received
2nd and 3rd-line therapy, respectively. More patients were
treated in 2nd-line after 1 January 2011. After a median
follow-up of 55.1 months, median progression-free (PFS) and
overall survival (OS) were 10.7 (95% confidence intervals [CI]:
8.3-13.7), 7.3 (95% CI: 5.1-8.6), 5.8 (95% CI: 3.8-7.8) and 34
(95% CI: 28.5-39.8), 22.4 (95% CI: 16-32.1), 18.3 (95% CI:
12.4-26.4) months for first, second and third line, respectively.
Efficacy of sunitinib and pazopanib in 1st-line were similar. The
mean total cost/patient was 35,012.2 Euros (standard deviation
[SD]: 28,971.5). Conclusions: Our study confirms previous
real-world data suggesting that continuing advances in the
treatment of mRCC produce favorable outcomes in everyday
practice. Pharmacoeconomic analyses are important for
cost-effective utilization of emerging novel therapies.
Beletsi, Alexandra; Koutrafouri, Vassiliki; Karampli, Eleftheria; Pavi, Elpida
Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union Journal Article
In: Value Health Reg Issues, vol. 16, pp. 81–91, 2018.
Abstract | BibTeX | Ετικέτες: health policies; health technology assessment; pharmacoeconomics; reimbursement
@article{Beletsi2018-jr,
title = {Comparing Use of Health Technology Assessment in Pharmaceutical
Policy among Earlier and More Recent Adopters in the European
Union},
author = {Alexandra Beletsi and Vassiliki Koutrafouri and Eleftheria Karampli and Elpida Pavi},
year = {2018},
date = {2018-10-01},
journal = {Value Health Reg Issues},
volume = {16},
pages = {81--91},
address = {United States},
abstract = {OBJECTIVES: To examine and compare the use of health technology
assessment (HTA) for the reimbursement of new medicines in
selected European Union member states with decades of experience
in the use of HTA and in countries that have used it regularly
since 2000. METHODS: The selected countries were categorized into
``earlier'' adopters (group A: England, Germany, France, and
Sweden) and more ``recent'' adopters (group B: Poland, Bulgaria,
Hungary, and Romania). A systematic review of published
literature was performed. The analysis and comparison of HTA
procedures were done by using an analytical framework. RESULTS:
In all countries, the assessment criteria used include
effectiveness, safety, relative effectiveness, and economic data.
In group A countries, the main objectives are improving quality
of care, ensuring equal access, and efficient use of resources.
Group B countries have established HTA organizations with
official guidelines but often seek the decisions of other
developed countries. They place considerable emphasis on the
budget impact of new therapies, and HTA is also used as a cost
estimation tool for state budgets. CONCLUSIONS: HTA organizations
have been developed dynamically not only in high-income countries
but also in countries with limited resources. The experience and
evolution of both can be used by countries that are in the dawn
of creating an HTA organization.},
keywords = {health policies; health technology assessment; pharmacoeconomics; reimbursement},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVES: To examine and compare the use of health technology
assessment (HTA) for the reimbursement of new medicines in
selected European Union member states with decades of experience
in the use of HTA and in countries that have used it regularly
since 2000. METHODS: The selected countries were categorized into
``earlier'' adopters (group A: England, Germany, France, and
Sweden) and more ``recent'' adopters (group B: Poland, Bulgaria,
Hungary, and Romania). A systematic review of published
literature was performed. The analysis and comparison of HTA
procedures were done by using an analytical framework. RESULTS:
In all countries, the assessment criteria used include
effectiveness, safety, relative effectiveness, and economic data.
In group A countries, the main objectives are improving quality
of care, ensuring equal access, and efficient use of resources.
Group B countries have established HTA organizations with
official guidelines but often seek the decisions of other
developed countries. They place considerable emphasis on the
budget impact of new therapies, and HTA is also used as a cost
estimation tool for state budgets. CONCLUSIONS: HTA organizations
have been developed dynamically not only in high-income countries
but also in countries with limited resources. The experience and
evolution of both can be used by countries that are in the dawn
of creating an HTA organization.
assessment (HTA) for the reimbursement of new medicines in
selected European Union member states with decades of experience
in the use of HTA and in countries that have used it regularly
since 2000. METHODS: The selected countries were categorized into
``earlier'' adopters (group A: England, Germany, France, and
Sweden) and more ``recent'' adopters (group B: Poland, Bulgaria,
Hungary, and Romania). A systematic review of published
literature was performed. The analysis and comparison of HTA
procedures were done by using an analytical framework. RESULTS:
In all countries, the assessment criteria used include
effectiveness, safety, relative effectiveness, and economic data.
In group A countries, the main objectives are improving quality
of care, ensuring equal access, and efficient use of resources.
Group B countries have established HTA organizations with
official guidelines but often seek the decisions of other
developed countries. They place considerable emphasis on the
budget impact of new therapies, and HTA is also used as a cost
estimation tool for state budgets. CONCLUSIONS: HTA organizations
have been developed dynamically not only in high-income countries
but also in countries with limited resources. The experience and
evolution of both can be used by countries that are in the dawn
of creating an HTA organization.
Kyriopoulos, Ilias; Athanasakis, Kostas; Kyriopoulos, John
Are happy people healthier? An instrumental variable approach using data from Greece Journal Article
In: J Epidemiol Community Health, vol. 72, no. 12, pp. 1153–1161, 2018.
Abstract | BibTeX | Ετικέτες: prevention; public health policy; self-rated health; socioeconomic
@article{Kyriopoulos2018-ck,
title = {Are happy people healthier? An instrumental variable approach
using data from Greece},
author = {Ilias Kyriopoulos and Kostas Athanasakis and John Kyriopoulos},
year = {2018},
date = {2018-07-01},
journal = {J Epidemiol Community Health},
volume = {72},
number = {12},
pages = {1153--1161},
address = {England},
abstract = {BACKGROUND: From a theoretical perspective, several studies
indicate that happiness and health are-in some
extent-interrelated. Despite the mechanisms explaining the
relationship between happiness and health, there is still no
consensus regarding this link. Using recently collected primary
data, this study aims to examine the relationship between
happiness and health, and identify potential heterogeneity in the
association depending on socioeconomic status (SES). METHODS:
This study draws on data from a nationally representative
cross-sectional survey, conducted by the Greek National School of
Public Health in 2015. We applied an instrumental variable (IV)
approach to address the endogeneity, arising from the
simultaneous determination of happiness and health. Controlling
for several confounders (ie, socioeconomic, demographic,
lifestyle, social capital variables) we employed several IV
models, including two-stage least squares, IV probit and
bivariate probit models. RESULTS: We report strong evidence of a
relationship between happiness and health. This association
remains strong after correcting for endogeneity, and is robust
across different specifications. Further, we find a positive
relationship between happiness and self-rated health (SRH) for
low educated, but not for high educated. Similarly, we find a
strong relationship between happiness and health for the lower
socioeconomic strata, but not for the higher ones. CONCLUSIONS:
Overall, we show that happiness is positively associated with
health. Further, happiness significantly influences SRH in
low-SES individuals, but this association wanes for the higher
socioeconomic strata. This finding has significant implications
for health promotion, prevention and public health, and suggests
that policymakers have a wider array of choices for improving
health and tackling health inequalities.},
keywords = {prevention; public health policy; self-rated health; socioeconomic},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: From a theoretical perspective, several studies
indicate that happiness and health are-in some
extent-interrelated. Despite the mechanisms explaining the
relationship between happiness and health, there is still no
consensus regarding this link. Using recently collected primary
data, this study aims to examine the relationship between
happiness and health, and identify potential heterogeneity in the
association depending on socioeconomic status (SES). METHODS:
This study draws on data from a nationally representative
cross-sectional survey, conducted by the Greek National School of
Public Health in 2015. We applied an instrumental variable (IV)
approach to address the endogeneity, arising from the
simultaneous determination of happiness and health. Controlling
for several confounders (ie, socioeconomic, demographic,
lifestyle, social capital variables) we employed several IV
models, including two-stage least squares, IV probit and
bivariate probit models. RESULTS: We report strong evidence of a
relationship between happiness and health. This association
remains strong after correcting for endogeneity, and is robust
across different specifications. Further, we find a positive
relationship between happiness and self-rated health (SRH) for
low educated, but not for high educated. Similarly, we find a
strong relationship between happiness and health for the lower
socioeconomic strata, but not for the higher ones. CONCLUSIONS:
Overall, we show that happiness is positively associated with
health. Further, happiness significantly influences SRH in
low-SES individuals, but this association wanes for the higher
socioeconomic strata. This finding has significant implications
for health promotion, prevention and public health, and suggests
that policymakers have a wider array of choices for improving
health and tackling health inequalities.
indicate that happiness and health are-in some
extent-interrelated. Despite the mechanisms explaining the
relationship between happiness and health, there is still no
consensus regarding this link. Using recently collected primary
data, this study aims to examine the relationship between
happiness and health, and identify potential heterogeneity in the
association depending on socioeconomic status (SES). METHODS:
This study draws on data from a nationally representative
cross-sectional survey, conducted by the Greek National School of
Public Health in 2015. We applied an instrumental variable (IV)
approach to address the endogeneity, arising from the
simultaneous determination of happiness and health. Controlling
for several confounders (ie, socioeconomic, demographic,
lifestyle, social capital variables) we employed several IV
models, including two-stage least squares, IV probit and
bivariate probit models. RESULTS: We report strong evidence of a
relationship between happiness and health. This association
remains strong after correcting for endogeneity, and is robust
across different specifications. Further, we find a positive
relationship between happiness and self-rated health (SRH) for
low educated, but not for high educated. Similarly, we find a
strong relationship between happiness and health for the lower
socioeconomic strata, but not for the higher ones. CONCLUSIONS:
Overall, we show that happiness is positively associated with
health. Further, happiness significantly influences SRH in
low-SES individuals, but this association wanes for the higher
socioeconomic strata. This finding has significant implications
for health promotion, prevention and public health, and suggests
that policymakers have a wider array of choices for improving
health and tackling health inequalities.
Tentolouris, Anastasios; Eleftheriadou, Ioanna; Athanasakis, Kostas; Kyriopoulos, John; Tsilimigras, Diamantis I; Grigoropoulou, Pinelopi; Doupis, John; Tentolouris, Nikolaos
Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population Journal Article
In: Hellenic J Cardiol, vol. 61, no. 1, pp. 15–22, 2018.
Abstract | BibTeX | Ετικέτες: Comorbidities; Diabetes mellitus; General population; Heart disease; Prevalence
@article{Tentolouris2018-xd,
title = {Prevalence of diabetes mellitus as well as cardiac and other main
comorbidities in a representative sample of the adult Greek
population in comparison with the general population},
author = {Anastasios Tentolouris and Ioanna Eleftheriadou and Kostas Athanasakis and John Kyriopoulos and Diamantis I Tsilimigras and Pinelopi Grigoropoulou and John Doupis and Nikolaos Tentolouris},
year = {2018},
date = {2018-05-01},
journal = {Hellenic J Cardiol},
volume = {61},
number = {1},
pages = {15--22},
address = {Netherlands},
abstract = {BACKGROUND: Diabetes mellitus (DM) is the most common metabolic
disorder that increases the risk of cardiovascular disease by two
to four times compared with the general population. There are
limited data on the prevalence of heart diseases in subjects with
DM in Greece. In this study, we examined the prevalence of
self-reported DM as well as cardiac and other main comorbidities
in a representative sample of the adult Greek population.
METHODS: The target study population included 30,843 participants
stratified by gender, age, and district, and this was a
representative sample of the adult Greek population in 2010. A
structured questionnaire was built to report the prevalence of
self-reported DM and the main comorbidities in participants with
and without DM. Collection of data was performed through
telephone interviews. RESULTS: The prevalence of self-reported DM
was 6.6%. The prevalence of the main comorbidities in
participants with DM vs. those without DM was as follows: heart
diseases 24.0% vs. 8.9%, p<0.001; lung diseases 11.3% vs. 5.3%, p<0.001; kidney diseases 3.4% vs. 1.2},
keywords = {Comorbidities; Diabetes mellitus; General population; Heart disease; Prevalence},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Diabetes mellitus (DM) is the most common metabolic
disorder that increases the risk of cardiovascular disease by two
to four times compared with the general population. There are
limited data on the prevalence of heart diseases in subjects with
DM in Greece. In this study, we examined the prevalence of
self-reported DM as well as cardiac and other main comorbidities
in a representative sample of the adult Greek population.
METHODS: The target study population included 30,843 participants
stratified by gender, age, and district, and this was a
representative sample of the adult Greek population in 2010. A
structured questionnaire was built to report the prevalence of
self-reported DM and the main comorbidities in participants with
and without DM. Collection of data was performed through
telephone interviews. RESULTS: The prevalence of self-reported DM
was 6.6%. The prevalence of the main comorbidities in
participants with DM vs. those without DM was as follows: heart
diseases 24.0% vs. 8.9%, p<0.001; lung diseases 11.3% vs. 5.3%, p<0.001; kidney diseases 3.4% vs. 1.2
disorder that increases the risk of cardiovascular disease by two
to four times compared with the general population. There are
limited data on the prevalence of heart diseases in subjects with
DM in Greece. In this study, we examined the prevalence of
self-reported DM as well as cardiac and other main comorbidities
in a representative sample of the adult Greek population.
METHODS: The target study population included 30,843 participants
stratified by gender, age, and district, and this was a
representative sample of the adult Greek population in 2010. A
structured questionnaire was built to report the prevalence of
self-reported DM and the main comorbidities in participants with
and without DM. Collection of data was performed through
telephone interviews. RESULTS: The prevalence of self-reported DM
was 6.6%. The prevalence of the main comorbidities in
participants with DM vs. those without DM was as follows: heart
diseases 24.0% vs. 8.9%, p<0.001; lung diseases 11.3% vs. 5.3%, p<0.001; kidney diseases 3.4% vs. 1.2
Collaborators, Polaris Observatory
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study Journal Article
In: Lancet Gastroenterol Hepatol, vol. 3, no. 6, pp. 383–403, 2018.
@article{Polaris_Observatory_Collaborators2018-xp,
title = {Global prevalence, treatment, and prevention of hepatitis B
virus infection in 2016: a modelling study},
author = {Polaris Observatory Collaborators},
year = {2018},
date = {2018-03-01},
journal = {Lancet Gastroenterol Hepatol},
volume = {3},
number = {6},
pages = {383--403},
address = {Netherlands},
abstract = {BACKGROUND: The 69th World Health Assembly approved the Global
Health Sector Strategy to eliminate viral hepatitis by 2030.
Although no virological cure exists for hepatitis B virus (HBV)
infection, existing therapies to control viral replication and
prophylaxis to minimise mother-to-child transmission make
elimination of HBV feasible. We aimed to estimate the national,
regional, and global prevalence of HBsAg in the general
population and in the population aged 5 years in 2016, as well as
coverage of prophylaxis, diagnosis, and treatment. METHODS: In
this modelling study, we used a Delphi process that included a
literature review in PubMed and Embase, followed by interviews
with experts, to quantify the historical epidemiology of HBV
infection. We then used a dynamic HBV transmission and
progression model to estimate the country-level and
regional-level prevalence of HBsAg in 2016 and the effect of
prophylaxis and treatment on disease burden. FINDINGS: We
developed models for 120 countries, 78 of which were populated
with data approved by experts. Using these models, we estimated
that the global prevalence of HBsAg in 2016 was 3·9% (95%
uncertainty interval [UI] 3·4-4·6), corresponding to 291 992 000
(251 513 000-341 114 000) infections. Of these infections, around
29 million (10%) were diagnosed, and only 4·8 million (5%) of
94 million individuals eligible for treatment actually received
antiviral therapy. Around 1·8 (1·6-2·2) million infections were
in children aged 5 years, with a prevalence of 1·4% (1·2-1·6).
We estimated that 87% of infants had received the three-dose HBV
vaccination in the first year of life, 46% had received timely
birth-dose vaccination, and 13% had received hepatitis B
immunoglobulin along with the full vaccination regimen. Less than
1% of mothers with a high viral load had received antiviral
therapy to reduce mother-to-child transmission. INTERPRETATION:
Our estimate of HBV prevalence in 2016 differs from previous
studies, potentially because we took into account the effect of
infant prophylaxis and early childhood vaccination, as well as
changing prevalence over time. Although some regions are well on
their way to meeting prophylaxis and prevalence targets, all
regions must substantially scale-up access to diagnosis and
treatment to meet the global targets. FUNDING: John C Martin
Foundation.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: The 69th World Health Assembly approved the Global
Health Sector Strategy to eliminate viral hepatitis by 2030.
Although no virological cure exists for hepatitis B virus (HBV)
infection, existing therapies to control viral replication and
prophylaxis to minimise mother-to-child transmission make
elimination of HBV feasible. We aimed to estimate the national,
regional, and global prevalence of HBsAg in the general
population and in the population aged 5 years in 2016, as well as
coverage of prophylaxis, diagnosis, and treatment. METHODS: In
this modelling study, we used a Delphi process that included a
literature review in PubMed and Embase, followed by interviews
with experts, to quantify the historical epidemiology of HBV
infection. We then used a dynamic HBV transmission and
progression model to estimate the country-level and
regional-level prevalence of HBsAg in 2016 and the effect of
prophylaxis and treatment on disease burden. FINDINGS: We
developed models for 120 countries, 78 of which were populated
with data approved by experts. Using these models, we estimated
that the global prevalence of HBsAg in 2016 was 3·9% (95%
uncertainty interval [UI] 3·4-4·6), corresponding to 291 992 000
(251 513 000-341 114 000) infections. Of these infections, around
29 million (10%) were diagnosed, and only 4·8 million (5%) of
94 million individuals eligible for treatment actually received
antiviral therapy. Around 1·8 (1·6-2·2) million infections were
in children aged 5 years, with a prevalence of 1·4% (1·2-1·6).
We estimated that 87% of infants had received the three-dose HBV
vaccination in the first year of life, 46% had received timely
birth-dose vaccination, and 13% had received hepatitis B
immunoglobulin along with the full vaccination regimen. Less than
1% of mothers with a high viral load had received antiviral
therapy to reduce mother-to-child transmission. INTERPRETATION:
Our estimate of HBV prevalence in 2016 differs from previous
studies, potentially because we took into account the effect of
infant prophylaxis and early childhood vaccination, as well as
changing prevalence over time. Although some regions are well on
their way to meeting prophylaxis and prevalence targets, all
regions must substantially scale-up access to diagnosis and
treatment to meet the global targets. FUNDING: John C Martin
Foundation.
Health Sector Strategy to eliminate viral hepatitis by 2030.
Although no virological cure exists for hepatitis B virus (HBV)
infection, existing therapies to control viral replication and
prophylaxis to minimise mother-to-child transmission make
elimination of HBV feasible. We aimed to estimate the national,
regional, and global prevalence of HBsAg in the general
population and in the population aged 5 years in 2016, as well as
coverage of prophylaxis, diagnosis, and treatment. METHODS: In
this modelling study, we used a Delphi process that included a
literature review in PubMed and Embase, followed by interviews
with experts, to quantify the historical epidemiology of HBV
infection. We then used a dynamic HBV transmission and
progression model to estimate the country-level and
regional-level prevalence of HBsAg in 2016 and the effect of
prophylaxis and treatment on disease burden. FINDINGS: We
developed models for 120 countries, 78 of which were populated
with data approved by experts. Using these models, we estimated
that the global prevalence of HBsAg in 2016 was 3·9% (95%
uncertainty interval [UI] 3·4-4·6), corresponding to 291 992 000
(251 513 000-341 114 000) infections. Of these infections, around
29 million (10%) were diagnosed, and only 4·8 million (5%) of
94 million individuals eligible for treatment actually received
antiviral therapy. Around 1·8 (1·6-2·2) million infections were
in children aged 5 years, with a prevalence of 1·4% (1·2-1·6).
We estimated that 87% of infants had received the three-dose HBV
vaccination in the first year of life, 46% had received timely
birth-dose vaccination, and 13% had received hepatitis B
immunoglobulin along with the full vaccination regimen. Less than
1% of mothers with a high viral load had received antiviral
therapy to reduce mother-to-child transmission. INTERPRETATION:
Our estimate of HBV prevalence in 2016 differs from previous
studies, potentially because we took into account the effect of
infant prophylaxis and early childhood vaccination, as well as
changing prevalence over time. Although some regions are well on
their way to meeting prophylaxis and prevalence targets, all
regions must substantially scale-up access to diagnosis and
treatment to meet the global targets. FUNDING: John C Martin
Foundation.
Mahdavi, Mahdi; Vissers, Jan; Elkhuizen, Sylvia; Dijk, Mattees; Vanhala, Antero; Karampli, Eleftheria; Faubel, Raquel; Forte, Paul; Coroian, Elena; Klundert, Joris
The relationship between context, structure, and processes with outcomes of 6 regional diabetes networks in Europe Journal Article
In: PLoS One, vol. 13, no. 2, pp. e0192599, 2018.
@article{Mahdavi2018-xz,
title = {The relationship between context, structure, and processes with
outcomes of 6 regional diabetes networks in Europe},
author = {Mahdi Mahdavi and Jan Vissers and Sylvia Elkhuizen and Mattees Dijk and Antero Vanhala and Eleftheria Karampli and Raquel Faubel and Paul Forte and Elena Coroian and Joris Klundert},
year = {2018},
date = {2018-02-01},
journal = {PLoS One},
volume = {13},
number = {2},
pages = {e0192599},
abstract = {BACKGROUND: While health service provisioning for the chronic
condition Type 2 Diabetes (T2D) often involves a network of
organisations and professionals, most evidence on the
relationships between the structures and processes of service
provisioning and the outcomes considers single organisations or
solo practitioners. Extending Donabedian's
Structure-Process-Outcome (SPO) model, we investigate how
differences in quality of life, effective coverage of diabetes,
and service satisfaction are associated with differences in the
structures, processes, and context of T2D services in six regions
in Finland, Germany, Greece, Netherlands, Spain, and UK. METHODS:
Data collection consisted of: a) systematic modelling of provider
network's structures and processes, and b) a cross-sectional
survey of patient reported outcomes and other information. The
survey resulted in data from 1459 T2D patients, during 2011-2012.
Stepwise linear regression models were used to identify how
independent cumulative proportion of variance in quality of life
and service satisfaction are related to differences in context,
structure and process. The selected context, structure and
process variables are based on Donabedian's SPO model, a service
quality research instrument (SERVQUAL), and previous organization
and professional level evidence. Additional analysis deepens the
possible bidirectional relation between outcomes and processes.
RESULTS: The regression models explain 44% of variance in
service satisfaction, mostly by structure and process variables
(such as human resource use and the SERVQUAL dimensions). The
models explained 23% of variance in quality of life between the
networks, much of which is related to contextual variables. Our
results suggest that effectiveness of A1c control is negatively
correlated with process variables such as total hours of care
provided per year and cost of services per year. CONCLUSIONS:
While the selected structure and process variables explain much
of the variance in service satisfaction, this is less the case
for quality of life. Moreover, it appears that the effect of the
clinical outcome A1c control on processes is stronger than the
other way around, as poorer control seems to relate to more
service use, and higher cost. The standardized operational models
used in this research prove to form a basis for expanding the
network level evidence base for effective T2D service
provisioning.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: While health service provisioning for the chronic
condition Type 2 Diabetes (T2D) often involves a network of
organisations and professionals, most evidence on the
relationships between the structures and processes of service
provisioning and the outcomes considers single organisations or
solo practitioners. Extending Donabedian's
Structure-Process-Outcome (SPO) model, we investigate how
differences in quality of life, effective coverage of diabetes,
and service satisfaction are associated with differences in the
structures, processes, and context of T2D services in six regions
in Finland, Germany, Greece, Netherlands, Spain, and UK. METHODS:
Data collection consisted of: a) systematic modelling of provider
network's structures and processes, and b) a cross-sectional
survey of patient reported outcomes and other information. The
survey resulted in data from 1459 T2D patients, during 2011-2012.
Stepwise linear regression models were used to identify how
independent cumulative proportion of variance in quality of life
and service satisfaction are related to differences in context,
structure and process. The selected context, structure and
process variables are based on Donabedian's SPO model, a service
quality research instrument (SERVQUAL), and previous organization
and professional level evidence. Additional analysis deepens the
possible bidirectional relation between outcomes and processes.
RESULTS: The regression models explain 44% of variance in
service satisfaction, mostly by structure and process variables
(such as human resource use and the SERVQUAL dimensions). The
models explained 23% of variance in quality of life between the
networks, much of which is related to contextual variables. Our
results suggest that effectiveness of A1c control is negatively
correlated with process variables such as total hours of care
provided per year and cost of services per year. CONCLUSIONS:
While the selected structure and process variables explain much
of the variance in service satisfaction, this is less the case
for quality of life. Moreover, it appears that the effect of the
clinical outcome A1c control on processes is stronger than the
other way around, as poorer control seems to relate to more
service use, and higher cost. The standardized operational models
used in this research prove to form a basis for expanding the
network level evidence base for effective T2D service
provisioning.
condition Type 2 Diabetes (T2D) often involves a network of
organisations and professionals, most evidence on the
relationships between the structures and processes of service
provisioning and the outcomes considers single organisations or
solo practitioners. Extending Donabedian's
Structure-Process-Outcome (SPO) model, we investigate how
differences in quality of life, effective coverage of diabetes,
and service satisfaction are associated with differences in the
structures, processes, and context of T2D services in six regions
in Finland, Germany, Greece, Netherlands, Spain, and UK. METHODS:
Data collection consisted of: a) systematic modelling of provider
network's structures and processes, and b) a cross-sectional
survey of patient reported outcomes and other information. The
survey resulted in data from 1459 T2D patients, during 2011-2012.
Stepwise linear regression models were used to identify how
independent cumulative proportion of variance in quality of life
and service satisfaction are related to differences in context,
structure and process. The selected context, structure and
process variables are based on Donabedian's SPO model, a service
quality research instrument (SERVQUAL), and previous organization
and professional level evidence. Additional analysis deepens the
possible bidirectional relation between outcomes and processes.
RESULTS: The regression models explain 44% of variance in
service satisfaction, mostly by structure and process variables
(such as human resource use and the SERVQUAL dimensions). The
models explained 23% of variance in quality of life between the
networks, much of which is related to contextual variables. Our
results suggest that effectiveness of A1c control is negatively
correlated with process variables such as total hours of care
provided per year and cost of services per year. CONCLUSIONS:
While the selected structure and process variables explain much
of the variance in service satisfaction, this is less the case
for quality of life. Moreover, it appears that the effect of the
clinical outcome A1c control on processes is stronger than the
other way around, as poorer control seems to relate to more
service use, and higher cost. The standardized operational models
used in this research prove to form a basis for expanding the
network level evidence base for effective T2D service
provisioning.
Naoum, Panagiota; Skroumpelos, Anastasis; Athanasakis, Kostas; Kyriopoulos, John
Factors associated with the utilization of mammographic screening in Greece Journal Article
In: Eur J Cancer Prev, vol. 27, no. 1, pp. 13–19, 2018.
@article{Naoum2018-lg,
title = {Factors associated with the utilization of mammographic screening
in Greece},
author = {Panagiota Naoum and Anastasis Skroumpelos and Kostas Athanasakis and John Kyriopoulos},
year = {2018},
date = {2018-01-01},
journal = {Eur J Cancer Prev},
volume = {27},
number = {1},
pages = {13--19},
address = {England},
abstract = {Breast cancer is the most commonly diagnosed type of cancer in
women and the primary cause of death by cancer in women globally.
Early diagnosis and treatment can be achieved through screening,
mainly mammographic; however, international experience has shown
that women do not attend mammographic screening adequately. The
aim of the present study was to investigate and assess the
factors that affect demand for mammography by women to improve
and enhance the use of mammography by women in Greece, especially
those in the 50-70 age group. The data used in the analysis were
extracted from the National Health Survey of 2009, conducted by
the Hellenic Statistical Authority. The sample for the analysis
included 2294 women aged 30-70 years. To investigate the factors
that affect mammography use, binary logistic regression models
were constructed for women in the 30-39, 40-49 and 50-70 age
groups. 61.70% of the sample had ever undergone a mammogram,
46.80% of which were during the last 12 months. Factors
associated with mammography use in at least one of the binary
logistic regression models were pap-test, blood cholesterol test,
level of education, income level and country of birth. In the 50-70 age group, income level [odds ratio (OR)=1.164; 95% confidence interval (CI)=1.038, 1.305], blood cholesterol test ever (OR=6.096; 95% CI=2.498, 14.872) and pap-test (OR=20.148; 95% CI=11.264, 36.040) were found to be statistically
significant predictors of mammography uptake. As mammography
utilization in Greece is mostly opportunistic, it is necessary to
organize screening provision to cover the majority of the
population through nationally organized screening programmes,
with a focus on women 50-70 years of age.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Breast cancer is the most commonly diagnosed type of cancer in
women and the primary cause of death by cancer in women globally.
Early diagnosis and treatment can be achieved through screening,
mainly mammographic; however, international experience has shown
that women do not attend mammographic screening adequately. The
aim of the present study was to investigate and assess the
factors that affect demand for mammography by women to improve
and enhance the use of mammography by women in Greece, especially
those in the 50-70 age group. The data used in the analysis were
extracted from the National Health Survey of 2009, conducted by
the Hellenic Statistical Authority. The sample for the analysis
included 2294 women aged 30-70 years. To investigate the factors
that affect mammography use, binary logistic regression models
were constructed for women in the 30-39, 40-49 and 50-70 age
groups. 61.70% of the sample had ever undergone a mammogram,
46.80% of which were during the last 12 months. Factors
associated with mammography use in at least one of the binary
logistic regression models were pap-test, blood cholesterol test,
level of education, income level and country of birth. In the 50-70 age group, income level [odds ratio (OR)=1.164; 95% confidence interval (CI)=1.038, 1.305], blood cholesterol test ever (OR=6.096; 95% CI=2.498, 14.872) and pap-test (OR=20.148; 95% CI=11.264, 36.040) were found to be statistically
significant predictors of mammography uptake. As mammography
utilization in Greece is mostly opportunistic, it is necessary to
organize screening provision to cover the majority of the
population through nationally organized screening programmes,
with a focus on women 50-70 years of age.
women and the primary cause of death by cancer in women globally.
Early diagnosis and treatment can be achieved through screening,
mainly mammographic; however, international experience has shown
that women do not attend mammographic screening adequately. The
aim of the present study was to investigate and assess the
factors that affect demand for mammography by women to improve
and enhance the use of mammography by women in Greece, especially
those in the 50-70 age group. The data used in the analysis were
extracted from the National Health Survey of 2009, conducted by
the Hellenic Statistical Authority. The sample for the analysis
included 2294 women aged 30-70 years. To investigate the factors
that affect mammography use, binary logistic regression models
were constructed for women in the 30-39, 40-49 and 50-70 age
groups. 61.70% of the sample had ever undergone a mammogram,
46.80% of which were during the last 12 months. Factors
associated with mammography use in at least one of the binary
logistic regression models were pap-test, blood cholesterol test,
level of education, income level and country of birth. In the 50-70 age group, income level [odds ratio (OR)=1.164; 95% confidence interval (CI)=1.038, 1.305], blood cholesterol test ever (OR=6.096; 95% CI=2.498, 14.872) and pap-test (OR=20.148; 95% CI=11.264, 36.040) were found to be statistically
significant predictors of mammography uptake. As mammography
utilization in Greece is mostly opportunistic, it is necessary to
organize screening provision to cover the majority of the
population through nationally organized screening programmes,
with a focus on women 50-70 years of age.
2017
Athanasakis, Kostas; Boubouchairopoulou, Nadia; Tarantilis, Filippos; Tsiantou, Vasiliki; Kontodimas, Stathis; Kyriopoulos, John
Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of Actinic Keratosis in Greece Journal Article
In: Clin Ther, vol. 39, no. 5, pp. 993–1002, 2017.
Abstract | BibTeX | Ετικέτες: actinic keratosis; cost; cost-effectiveness; ingenol mebutate; topical treatment
@article{Athanasakis2017-lu,
title = {Cost-effectiveness of Ingenol Mebutate Gel for the Treatment of
Actinic Keratosis in Greece},
author = {Kostas Athanasakis and Nadia Boubouchairopoulou and Filippos Tarantilis and Vasiliki Tsiantou and Stathis Kontodimas and John Kyriopoulos},
year = {2017},
date = {2017-04-01},
journal = {Clin Ther},
volume = {39},
number = {5},
pages = {993--1002},
address = {United States},
abstract = {PURPOSE: The present study aimed to perform a cost-effectiveness
analysis of ingenol mebutate (IM) versus other topical
alternatives for the treatment of actinic keratosis (AK).
METHODS: The analysis used a decision tree to calculate the
clinical effects and costs of AK first-line treatments, IM (2-3
days), diclofenac 3% (for 8 or 12 weeks), imiquimod 5% (for 4
or 8 weeks), during a 24-month horizon, using discrete intervals
of 6 months. A hypothetical cohort of immunocompetent adult
patients with clinically confirmed AK on the face and scalp or
trunk and extremities was considered. Clinical data on the
relative efficacy were obtained from a network meta-analysis.
Inputs concerning resource use derived from an expert panel. All
costs were calculated from a Greek third-party payer perspective.
FINDINGS: IM 0.015% and 0.05% were both cost-effective compared
with diclofenac and below a willingness-to-pay threshold of
€30,000 per quality-adjusted life-year (QALY) (€199 and €167 per
QALY, respectively). Comparing IM on the face and scalp AK
lesions for 3 days versus imiquimod for 4 weeks resulted in an
incremental cost-effectiveness ratio of €10,868 per QALY. IM was
dominant during the 8-week imiquimod period. IM use on the trunk
and extremities compared with diclofenac (8 or 12 weeks) led to
incremental cost-effectiveness ratios estimated at €1584 and
€1316 per QALY accordingly. Results remained robust to
deterministic and probabilistic sensitivity analyses.
IMPLICATIONS: From a social insurance perspective in Greece, IM
0.015% and IM 0.05% could be the most cost-effective first-line
topical field treatment options in all cases for AK treatment.},
keywords = {actinic keratosis; cost; cost-effectiveness; ingenol mebutate; topical treatment},
pubstate = {published},
tppubtype = {article}
}
PURPOSE: The present study aimed to perform a cost-effectiveness
analysis of ingenol mebutate (IM) versus other topical
alternatives for the treatment of actinic keratosis (AK).
METHODS: The analysis used a decision tree to calculate the
clinical effects and costs of AK first-line treatments, IM (2-3
days), diclofenac 3% (for 8 or 12 weeks), imiquimod 5% (for 4
or 8 weeks), during a 24-month horizon, using discrete intervals
of 6 months. A hypothetical cohort of immunocompetent adult
patients with clinically confirmed AK on the face and scalp or
trunk and extremities was considered. Clinical data on the
relative efficacy were obtained from a network meta-analysis.
Inputs concerning resource use derived from an expert panel. All
costs were calculated from a Greek third-party payer perspective.
FINDINGS: IM 0.015% and 0.05% were both cost-effective compared
with diclofenac and below a willingness-to-pay threshold of
€30,000 per quality-adjusted life-year (QALY) (€199 and €167 per
QALY, respectively). Comparing IM on the face and scalp AK
lesions for 3 days versus imiquimod for 4 weeks resulted in an
incremental cost-effectiveness ratio of €10,868 per QALY. IM was
dominant during the 8-week imiquimod period. IM use on the trunk
and extremities compared with diclofenac (8 or 12 weeks) led to
incremental cost-effectiveness ratios estimated at €1584 and
€1316 per QALY accordingly. Results remained robust to
deterministic and probabilistic sensitivity analyses.
IMPLICATIONS: From a social insurance perspective in Greece, IM
0.015% and IM 0.05% could be the most cost-effective first-line
topical field treatment options in all cases for AK treatment.
analysis of ingenol mebutate (IM) versus other topical
alternatives for the treatment of actinic keratosis (AK).
METHODS: The analysis used a decision tree to calculate the
clinical effects and costs of AK first-line treatments, IM (2-3
days), diclofenac 3% (for 8 or 12 weeks), imiquimod 5% (for 4
or 8 weeks), during a 24-month horizon, using discrete intervals
of 6 months. A hypothetical cohort of immunocompetent adult
patients with clinically confirmed AK on the face and scalp or
trunk and extremities was considered. Clinical data on the
relative efficacy were obtained from a network meta-analysis.
Inputs concerning resource use derived from an expert panel. All
costs were calculated from a Greek third-party payer perspective.
FINDINGS: IM 0.015% and 0.05% were both cost-effective compared
with diclofenac and below a willingness-to-pay threshold of
€30,000 per quality-adjusted life-year (QALY) (€199 and €167 per
QALY, respectively). Comparing IM on the face and scalp AK
lesions for 3 days versus imiquimod for 4 weeks resulted in an
incremental cost-effectiveness ratio of €10,868 per QALY. IM was
dominant during the 8-week imiquimod period. IM use on the trunk
and extremities compared with diclofenac (8 or 12 weeks) led to
incremental cost-effectiveness ratios estimated at €1584 and
€1316 per QALY accordingly. Results remained robust to
deterministic and probabilistic sensitivity analyses.
IMPLICATIONS: From a social insurance perspective in Greece, IM
0.015% and IM 0.05% could be the most cost-effective first-line
topical field treatment options in all cases for AK treatment.
Collaborators, European Union HCV
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study Journal Article
In: Lancet Gastroenterol Hepatol, vol. 2, no. 5, pp. 325–336, 2017.
@article{European_Union_HCV_Collaborators2017-le,
title = {Hepatitis C virus prevalence and level of intervention required
to achieve the WHO targets for elimination in the European
Union by 2030: a modelling study},
author = {European Union HCV Collaborators},
year = {2017},
date = {2017-03-01},
journal = {Lancet Gastroenterol Hepatol},
volume = {2},
number = {5},
pages = {325--336},
address = {Netherlands},
abstract = {BACKGROUND: Hepatitis C virus (HCV) is a leading cause of
liver-related morbidity and mortality worldwide. In the European
Union (EU), treatment and cure of HCV with direct-acting
antiviral therapies began in 2014. WHO targets are to achieve a
65% reduction in liver-related deaths, a 90% reduction of new
viral hepatitis infections, and 90% of patients with viral
hepatitis infections being diagnosed by 2030. This study assessed
the prevalence of HCV in the EU and the level of intervention
required to achieve WHO targets for HCV elimination. METHODS: We
populated country Markov models for the 28 EU countries through a
literature search of PubMed and Embase between Jan 1, 2000, and
March 31, 2016, and a Delphi process to gain expert consensus and
validate inputs. We aggregated country models to create a
regional EU model. We used the EU model to forecast HCV disease
progression (considering the effect of immigration) and developed
a strategy to acehive WHO targets. We used weighted average
sustained viral response rates and fibrosis restrictions to model
the effect of current therapeutic guidelines. We used the EU
model to forecast HCV disease progression (considering the effect
of immigration) under current screening and therapeutic
guidelines. Additionally, we back-calculated the total number of
patients needing to be screened and treated to achieve WHO
targets. FINDINGS: We estimated the number of viraemic HCV
infections in 2015 to be 3 238 000 (95% uncertainty interval
[UI] 2 106 000-3 795 000) of a total population of 509 868 000 in
the EU, equating to a prevalence of viraemic HCV of 0·64% (95%
UI 0·41-0·74). We estimated that 1 180 000 (95% UI 1 003 000-1
357 000) people were diagnosed with viraemia (36·4%), 150 000
(12 000-180 000) were treated (4·6% of the total infected
population or 12·7% of the diagnosed population), 133 000 (106
000-160 000) were cured (4·1%), and 57 900 (43 900-67 300) were
newly infected (1·8%) in 2015. Additionally, 30 400 (26 600-42
500) HCV-positive immigrants entered the EU. To achieve WHO
targets, unrestricted treatment needs to increase from 150 000
patients in 2015 to 187 000 patients in 2025 and diagnosis needs
to increase from 88 800 new cases annually in 2015 to 180 000 in
2025. INTERPRETATION: Given its advanced health-care
infrastructure, the EU is uniquely poised to eliminate HCV;
however, expansion of screening programmes is essential to
increase treatment to achieve the WHO targets. A united effort,
grounded in sound epidemiological evidence, will also be
necessary. FUNDING: Gilead Sciences.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Hepatitis C virus (HCV) is a leading cause of
liver-related morbidity and mortality worldwide. In the European
Union (EU), treatment and cure of HCV with direct-acting
antiviral therapies began in 2014. WHO targets are to achieve a
65% reduction in liver-related deaths, a 90% reduction of new
viral hepatitis infections, and 90% of patients with viral
hepatitis infections being diagnosed by 2030. This study assessed
the prevalence of HCV in the EU and the level of intervention
required to achieve WHO targets for HCV elimination. METHODS: We
populated country Markov models for the 28 EU countries through a
literature search of PubMed and Embase between Jan 1, 2000, and
March 31, 2016, and a Delphi process to gain expert consensus and
validate inputs. We aggregated country models to create a
regional EU model. We used the EU model to forecast HCV disease
progression (considering the effect of immigration) and developed
a strategy to acehive WHO targets. We used weighted average
sustained viral response rates and fibrosis restrictions to model
the effect of current therapeutic guidelines. We used the EU
model to forecast HCV disease progression (considering the effect
of immigration) under current screening and therapeutic
guidelines. Additionally, we back-calculated the total number of
patients needing to be screened and treated to achieve WHO
targets. FINDINGS: We estimated the number of viraemic HCV
infections in 2015 to be 3 238 000 (95% uncertainty interval
[UI] 2 106 000-3 795 000) of a total population of 509 868 000 in
the EU, equating to a prevalence of viraemic HCV of 0·64% (95%
UI 0·41-0·74). We estimated that 1 180 000 (95% UI 1 003 000-1
357 000) people were diagnosed with viraemia (36·4%), 150 000
(12 000-180 000) were treated (4·6% of the total infected
population or 12·7% of the diagnosed population), 133 000 (106
000-160 000) were cured (4·1%), and 57 900 (43 900-67 300) were
newly infected (1·8%) in 2015. Additionally, 30 400 (26 600-42
500) HCV-positive immigrants entered the EU. To achieve WHO
targets, unrestricted treatment needs to increase from 150 000
patients in 2015 to 187 000 patients in 2025 and diagnosis needs
to increase from 88 800 new cases annually in 2015 to 180 000 in
2025. INTERPRETATION: Given its advanced health-care
infrastructure, the EU is uniquely poised to eliminate HCV;
however, expansion of screening programmes is essential to
increase treatment to achieve the WHO targets. A united effort,
grounded in sound epidemiological evidence, will also be
necessary. FUNDING: Gilead Sciences.
liver-related morbidity and mortality worldwide. In the European
Union (EU), treatment and cure of HCV with direct-acting
antiviral therapies began in 2014. WHO targets are to achieve a
65% reduction in liver-related deaths, a 90% reduction of new
viral hepatitis infections, and 90% of patients with viral
hepatitis infections being diagnosed by 2030. This study assessed
the prevalence of HCV in the EU and the level of intervention
required to achieve WHO targets for HCV elimination. METHODS: We
populated country Markov models for the 28 EU countries through a
literature search of PubMed and Embase between Jan 1, 2000, and
March 31, 2016, and a Delphi process to gain expert consensus and
validate inputs. We aggregated country models to create a
regional EU model. We used the EU model to forecast HCV disease
progression (considering the effect of immigration) and developed
a strategy to acehive WHO targets. We used weighted average
sustained viral response rates and fibrosis restrictions to model
the effect of current therapeutic guidelines. We used the EU
model to forecast HCV disease progression (considering the effect
of immigration) under current screening and therapeutic
guidelines. Additionally, we back-calculated the total number of
patients needing to be screened and treated to achieve WHO
targets. FINDINGS: We estimated the number of viraemic HCV
infections in 2015 to be 3 238 000 (95% uncertainty interval
[UI] 2 106 000-3 795 000) of a total population of 509 868 000 in
the EU, equating to a prevalence of viraemic HCV of 0·64% (95%
UI 0·41-0·74). We estimated that 1 180 000 (95% UI 1 003 000-1
357 000) people were diagnosed with viraemia (36·4%), 150 000
(12 000-180 000) were treated (4·6% of the total infected
population or 12·7% of the diagnosed population), 133 000 (106
000-160 000) were cured (4·1%), and 57 900 (43 900-67 300) were
newly infected (1·8%) in 2015. Additionally, 30 400 (26 600-42
500) HCV-positive immigrants entered the EU. To achieve WHO
targets, unrestricted treatment needs to increase from 150 000
patients in 2015 to 187 000 patients in 2025 and diagnosis needs
to increase from 88 800 new cases annually in 2015 to 180 000 in
2025. INTERPRETATION: Given its advanced health-care
infrastructure, the EU is uniquely poised to eliminate HCV;
however, expansion of screening programmes is essential to
increase treatment to achieve the WHO targets. A united effort,
grounded in sound epidemiological evidence, will also be
necessary. FUNDING: Gilead Sciences.
Petrakis, Ioannis; Kyriopoulos, Ilias; Ginis, Alexandros; Athanasakis, Kostas
Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications Journal Article
In: Expert Rev Pharmacoecon Outcomes Res, vol. 17, no. 2, pp. 165–180, 2017.
Abstract | BibTeX | Ετικέτες: Cost; diabetes; diabetic foot; expenditure; health care expenditure
@article{Petrakis2017-wm,
title = {Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications},
author = {Ioannis Petrakis and Ilias Kyriopoulos and Alexandros Ginis and Kostas Athanasakis},
year = {2017},
date = {2017-03-01},
urldate = {2017-03-01},
journal = {Expert Rev Pharmacoecon Outcomes Res},
volume = {17},
number = {2},
pages = {165--180},
address = {England},
abstract = {Diabetes mellitus is a chronic disease with high prevalence
worldwide and a range of serious related complications. Amongst
them, diabetic foot is one of the most disabling, posing a
substantial health and economic burden on patients and healthcare
systems. Areas covered: According to projections, the expected
lower limb morbidity is about to increase - in this light the
present review aimed at identifying cost-of-illness studies on
the management and treatment of conditions related to the
diabetic foot, in an aim to provide a body of evidence for an
increasing health care burden. Expert commentary: Recent
literature review surfaced a plethora of cost studies. Despite
heterogeneity of foot complications and geographic variations,
the search methodology revealed substantial costs and further
healthcare burden for people with diabetes. Amputations due to
suboptimally treated foot infections contribute to the already
high rates of hospitalizations and readmissions. The cost of
amputation ranges between $35,000 and $45,000 in the developed
countries, however it largely depends on the amputation type.
Moreover, the findings suggest that the cost of amputation in the
US is generally higher compared to the cost in European
countries. The cost of amputation in developing countries is
substantially lower, as it approximates $5,000.},
keywords = {Cost; diabetes; diabetic foot; expenditure; health care expenditure},
pubstate = {published},
tppubtype = {article}
}
Diabetes mellitus is a chronic disease with high prevalence
worldwide and a range of serious related complications. Amongst
them, diabetic foot is one of the most disabling, posing a
substantial health and economic burden on patients and healthcare
systems. Areas covered: According to projections, the expected
lower limb morbidity is about to increase - in this light the
present review aimed at identifying cost-of-illness studies on
the management and treatment of conditions related to the
diabetic foot, in an aim to provide a body of evidence for an
increasing health care burden. Expert commentary: Recent
literature review surfaced a plethora of cost studies. Despite
heterogeneity of foot complications and geographic variations,
the search methodology revealed substantial costs and further
healthcare burden for people with diabetes. Amputations due to
suboptimally treated foot infections contribute to the already
high rates of hospitalizations and readmissions. The cost of
amputation ranges between $35,000 and $45,000 in the developed
countries, however it largely depends on the amputation type.
Moreover, the findings suggest that the cost of amputation in the
US is generally higher compared to the cost in European
countries. The cost of amputation in developing countries is
substantially lower, as it approximates $5,000.
worldwide and a range of serious related complications. Amongst
them, diabetic foot is one of the most disabling, posing a
substantial health and economic burden on patients and healthcare
systems. Areas covered: According to projections, the expected
lower limb morbidity is about to increase - in this light the
present review aimed at identifying cost-of-illness studies on
the management and treatment of conditions related to the
diabetic foot, in an aim to provide a body of evidence for an
increasing health care burden. Expert commentary: Recent
literature review surfaced a plethora of cost studies. Despite
heterogeneity of foot complications and geographic variations,
the search methodology revealed substantial costs and further
healthcare burden for people with diabetes. Amputations due to
suboptimally treated foot infections contribute to the already
high rates of hospitalizations and readmissions. The cost of
amputation ranges between $35,000 and $45,000 in the developed
countries, however it largely depends on the amputation type.
Moreover, the findings suggest that the cost of amputation in the
US is generally higher compared to the cost in European
countries. The cost of amputation in developing countries is
substantially lower, as it approximates $5,000.
Charonis, Antonios; Kyriopoulos, Ilias-Ioannis; Spanakis, Manos; Zavras, Dimitris; Athanasakis, Kostas; Pavi, Elpida; Kyriopoulos, John
Subjective social status, social network and health disparities: empirical evidence from Greece Journal Article
In: International Journal for Equity in Health, vol. 16, no. 1, 2017.
@article{Charonis2017,
title = {Subjective social status, social network and health disparities: empirical evidence from Greece},
author = {Antonios Charonis and Ilias-Ioannis Kyriopoulos and Manos Spanakis and Dimitris Zavras and Kostas Athanasakis and Elpida Pavi and John Kyriopoulos},
url = {https://doi.org/10.1186/s12939-017-0533-y},
doi = {10.1186/s12939-017-0533-y},
year = {2017},
date = {2017-02-01},
journal = {International Journal for Equity in Health},
volume = {16},
number = {1},
publisher = {Springer Science and Business Media LLC},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Intas, George; Kostagiolas, Petros; Zavras, Dimitris; Chalari, Eleftheria; Stergiannis, Pantelis; Toylia, Georgia; Niakas, Dimitris
Information-Seeking Behavior of Greek Nursing Students Journal Article
In: CIN: Computers, Informatics, Nursing, vol. 35, no. 2, pp. 109–114, 2017.
@article{Intas2017,
title = {Information-Seeking Behavior of Greek Nursing Students},
author = {George Intas and Petros Kostagiolas and Dimitris Zavras and Eleftheria Chalari and Pantelis Stergiannis and Georgia Toylia and Dimitris Niakas},
url = {https://doi.org/10.1097/cin.0000000000000294},
doi = {10.1097/cin.0000000000000294},
year = {2017},
date = {2017-02-01},
journal = {CIN: Computers, Informatics, Nursing},
volume = {35},
number = {2},
pages = {109--114},
publisher = {Ovid Technologies (Wolters Kluwer Health)},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Konerding, Uwe; Bowen, Tom; Elkhuizen, Sylvia G; Faubel, Raquel; Forte, Paul; Karampli, Eleftheria; Mahdavi, Mahdi; Malmström, Tomi; Pavi, Elpida; Torkki, Paulus
The impact of travel distance, travel time and waiting time on health-related quality of life of diabetes patients: An investigation in six European countries Journal Article
In: Diabetes Res Clin Pract, vol. 126, pp. 16–24, 2017.
Abstract | BibTeX | Ετικέτες: EQ-5D; Health-related quality of life; Travel distance to provider; Travel time to provider; Type 2 diabetes mellitus; Waiting time in provider's practice
@article{Konerding2017-yy,
title = {The impact of travel distance, travel time and waiting time on
health-related quality of life of diabetes patients: An
investigation in six European countries},
author = {Uwe Konerding and Tom Bowen and Sylvia G Elkhuizen and Raquel Faubel and Paul Forte and Eleftheria Karampli and Mahdi Mahdavi and Tomi Malmström and Elpida Pavi and Paulus Torkki},
year = {2017},
date = {2017-02-01},
journal = {Diabetes Res Clin Pract},
volume = {126},
pages = {16--24},
address = {Ireland},
abstract = {AIMS: The effects of travel distance and travel time to the
primary diabetes care provider and waiting time in the practice
on health-related quality of life (HRQoL) of patients with type 2
diabetes are investigated. RESEARCH DESIGN AND METHODS: Survey
data of 1313 persons with type 2 diabetes from six regions in
England (274), Finland (163), Germany (254), Greece (165), the
Netherlands (354), and Spain (103) were analyzed. Various
multiple linear regression analyses with four different EQ-5D-3L
indices (English, German, Dutch and Spanish index) as target
variables, with travel distance, travel time, and waiting time in
the practice as focal predictors and with control for study
region, patient's gender, patient's age, patient's education,
time since diagnosis, thoroughness of provider-patient
communication were computed. Interactions of regions with the
remaining five control variables and the three focal predictors
were also tested. RESULTS: There are no interactions of regions
with control variables or focal predictors. The indices decrease
with increasing travel time to the provider and increasing
waiting time in the provider's practice. CONCLUSIONS: HRQoL of
patients with type 2 diabetes might be improved by decreasing
travel time to the provider and waiting time in the provider's
practice.},
keywords = {EQ-5D; Health-related quality of life; Travel distance to provider; Travel time to provider; Type 2 diabetes mellitus; Waiting time in provider's practice},
pubstate = {published},
tppubtype = {article}
}
AIMS: The effects of travel distance and travel time to the
primary diabetes care provider and waiting time in the practice
on health-related quality of life (HRQoL) of patients with type 2
diabetes are investigated. RESEARCH DESIGN AND METHODS: Survey
data of 1313 persons with type 2 diabetes from six regions in
England (274), Finland (163), Germany (254), Greece (165), the
Netherlands (354), and Spain (103) were analyzed. Various
multiple linear regression analyses with four different EQ-5D-3L
indices (English, German, Dutch and Spanish index) as target
variables, with travel distance, travel time, and waiting time in
the practice as focal predictors and with control for study
region, patient's gender, patient's age, patient's education,
time since diagnosis, thoroughness of provider-patient
communication were computed. Interactions of regions with the
remaining five control variables and the three focal predictors
were also tested. RESULTS: There are no interactions of regions
with control variables or focal predictors. The indices decrease
with increasing travel time to the provider and increasing
waiting time in the provider's practice. CONCLUSIONS: HRQoL of
patients with type 2 diabetes might be improved by decreasing
travel time to the provider and waiting time in the provider's
practice.
primary diabetes care provider and waiting time in the practice
on health-related quality of life (HRQoL) of patients with type 2
diabetes are investigated. RESEARCH DESIGN AND METHODS: Survey
data of 1313 persons with type 2 diabetes from six regions in
England (274), Finland (163), Germany (254), Greece (165), the
Netherlands (354), and Spain (103) were analyzed. Various
multiple linear regression analyses with four different EQ-5D-3L
indices (English, German, Dutch and Spanish index) as target
variables, with travel distance, travel time, and waiting time in
the practice as focal predictors and with control for study
region, patient's gender, patient's age, patient's education,
time since diagnosis, thoroughness of provider-patient
communication were computed. Interactions of regions with the
remaining five control variables and the three focal predictors
were also tested. RESULTS: There are no interactions of regions
with control variables or focal predictors. The indices decrease
with increasing travel time to the provider and increasing
waiting time in the provider's practice. CONCLUSIONS: HRQoL of
patients with type 2 diabetes might be improved by decreasing
travel time to the provider and waiting time in the provider's
practice.
Charonis, Antonios; Kyriopoulos, Ilias-Ioannis; Spanakis, Manos; Zavras, Dimitris; Athanasakis, Kostas; Pavi, Elpida; Kyriopoulos, John
Subjective social status, social network and health disparities: empirical evidence from Greece Journal Article
In: Int J Equity Health, vol. 16, no. 1, pp. 40, 2017.
Abstract | BibTeX | Ετικέτες: Greece; Ordinal logistic regression; Self-rated health; Social network; Socioeconomic status; Subjective social status
@article{Charonis2017-cm,
title = {Subjective social status, social network and health disparities:
empirical evidence from Greece},
author = {Antonios Charonis and Ilias-Ioannis Kyriopoulos and Manos Spanakis and Dimitris Zavras and Kostas Athanasakis and Elpida Pavi and John Kyriopoulos},
year = {2017},
date = {2017-02-01},
journal = {Int J Equity Health},
volume = {16},
number = {1},
pages = {40},
abstract = {BACKGROUND: Several studies suggest that socioeconomic status
affects (SES) affects self-rated health (SRH), both in Greece and
internationally. However, prior research mainly uses objective
measures of SES, instead of subjective evaluations of
individuals' social status. Based on this, this paper aims to
examine (a) the impact of the economic dowturn on SRH in Greece
and (b) the relationship between subjective social status (SSS),
social network and SRH. METHODS: The descriptive analysis is
based on four cross-sectional surveys conducted by the National
School of Public Health, Athens, Greece (2002, 2006, 2011, 2015),
while the data for the empirical investigation were derived from
the 2015 survey (Health + Welfare Survey GR). The empirical
strategy is based on an ordinal logistic regression model, aiming
to examine how several variables affect SRH. Size of social
network and SSS are among the independent variables employed for
the empirical analysis RESULTS: According to our findings,
average SRH has deteriorated, and the percentage of the
population that reports very good/good SRH has also decreased.
Moreover, our empirical analysis suggests that age, existence of
a chronic disease, size of social network and SSS affect SRH in
Greece. CONCLUSION: Our findings are consistent with the existing
literature and confirm a social gradient in health. According to
our analysis, health disparities can be largely attributed to
socioeconomic inequalities. The adverse economic climate has
impact on socioeconomic differences which in turn affect health
disparities. Based on these, policy initiatives are necessasy in
order to mitigate the negative impact on health and the
disparities caused by economic dowturn and the occuring
socioeconomic inequalities.},
keywords = {Greece; Ordinal logistic regression; Self-rated health; Social network; Socioeconomic status; Subjective social status},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Several studies suggest that socioeconomic status
affects (SES) affects self-rated health (SRH), both in Greece and
internationally. However, prior research mainly uses objective
measures of SES, instead of subjective evaluations of
individuals' social status. Based on this, this paper aims to
examine (a) the impact of the economic dowturn on SRH in Greece
and (b) the relationship between subjective social status (SSS),
social network and SRH. METHODS: The descriptive analysis is
based on four cross-sectional surveys conducted by the National
School of Public Health, Athens, Greece (2002, 2006, 2011, 2015),
while the data for the empirical investigation were derived from
the 2015 survey (Health + Welfare Survey GR). The empirical
strategy is based on an ordinal logistic regression model, aiming
to examine how several variables affect SRH. Size of social
network and SSS are among the independent variables employed for
the empirical analysis RESULTS: According to our findings,
average SRH has deteriorated, and the percentage of the
population that reports very good/good SRH has also decreased.
Moreover, our empirical analysis suggests that age, existence of
a chronic disease, size of social network and SSS affect SRH in
Greece. CONCLUSION: Our findings are consistent with the existing
literature and confirm a social gradient in health. According to
our analysis, health disparities can be largely attributed to
socioeconomic inequalities. The adverse economic climate has
impact on socioeconomic differences which in turn affect health
disparities. Based on these, policy initiatives are necessasy in
order to mitigate the negative impact on health and the
disparities caused by economic dowturn and the occuring
socioeconomic inequalities.
affects (SES) affects self-rated health (SRH), both in Greece and
internationally. However, prior research mainly uses objective
measures of SES, instead of subjective evaluations of
individuals' social status. Based on this, this paper aims to
examine (a) the impact of the economic dowturn on SRH in Greece
and (b) the relationship between subjective social status (SSS),
social network and SRH. METHODS: The descriptive analysis is
based on four cross-sectional surveys conducted by the National
School of Public Health, Athens, Greece (2002, 2006, 2011, 2015),
while the data for the empirical investigation were derived from
the 2015 survey (Health + Welfare Survey GR). The empirical
strategy is based on an ordinal logistic regression model, aiming
to examine how several variables affect SRH. Size of social
network and SSS are among the independent variables employed for
the empirical analysis RESULTS: According to our findings,
average SRH has deteriorated, and the percentage of the
population that reports very good/good SRH has also decreased.
Moreover, our empirical analysis suggests that age, existence of
a chronic disease, size of social network and SSS affect SRH in
Greece. CONCLUSION: Our findings are consistent with the existing
literature and confirm a social gradient in health. According to
our analysis, health disparities can be largely attributed to
socioeconomic inequalities. The adverse economic climate has
impact on socioeconomic differences which in turn affect health
disparities. Based on these, policy initiatives are necessasy in
order to mitigate the negative impact on health and the
disparities caused by economic dowturn and the occuring
socioeconomic inequalities.
Athanasakis, Kostas
The Socioeconomic Effects of Uncontrolled Hypertension Journal Article
In: Curr Vasc Pharmacol, vol. 16, no. 1, pp. 5–9, 2017.
Abstract | BibTeX | Ετικέτες: Hypertension; cost; cost-effectiveness; health economics; health-related quality of life
@article{Athanasakis2017-hv,
title = {The Socioeconomic Effects of Uncontrolled Hypertension},
author = {Kostas Athanasakis},
year = {2017},
date = {2017-01-01},
journal = {Curr Vasc Pharmacol},
volume = {16},
number = {1},
pages = {5--9},
address = {United Arab Emirates},
abstract = {BACKGROUND: Hypertension (HT), albeit a modifiable risk factor of
cardiovascular morbidity and mortality, remains one of the main
contributors to the total disease burden internationally and,
thus, inevitably one of the basic cost drivers in healthcare
systems. CONCLUSION: Taking the above into account, this brief
narrative review aims at presenting the main findings of the
international health economics literature on HT with regards to
four key areas: a) the costs attributable to HT, b) the effects
of HT on patient well-being, c) the cost-effectiveness of
pharmaceutical interventions against high blood pressure, and, d)
the costs and benefits of preventive measures against HT. Bearing
in mind the available evidence on disease costs and the
efficiency of interventions, HT must constitute a primary
objective of modern health policy, internationally.},
keywords = {Hypertension; cost; cost-effectiveness; health economics; health-related quality of life},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Hypertension (HT), albeit a modifiable risk factor of
cardiovascular morbidity and mortality, remains one of the main
contributors to the total disease burden internationally and,
thus, inevitably one of the basic cost drivers in healthcare
systems. CONCLUSION: Taking the above into account, this brief
narrative review aims at presenting the main findings of the
international health economics literature on HT with regards to
four key areas: a) the costs attributable to HT, b) the effects
of HT on patient well-being, c) the cost-effectiveness of
pharmaceutical interventions against high blood pressure, and, d)
the costs and benefits of preventive measures against HT. Bearing
in mind the available evidence on disease costs and the
efficiency of interventions, HT must constitute a primary
objective of modern health policy, internationally.
cardiovascular morbidity and mortality, remains one of the main
contributors to the total disease burden internationally and,
thus, inevitably one of the basic cost drivers in healthcare
systems. CONCLUSION: Taking the above into account, this brief
narrative review aims at presenting the main findings of the
international health economics literature on HT with regards to
four key areas: a) the costs attributable to HT, b) the effects
of HT on patient well-being, c) the cost-effectiveness of
pharmaceutical interventions against high blood pressure, and, d)
the costs and benefits of preventive measures against HT. Bearing
in mind the available evidence on disease costs and the
efficiency of interventions, HT must constitute a primary
objective of modern health policy, internationally.
Balasopoulos, T; Charonis, A; Athanasakis, Kostas; Kyriopoulos, John; Pavi, Elpida
Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions Journal Article
In: Health Policy, vol. 121, no. 3, pp. 265–272, 2017.
Abstract | BibTeX | Ετικέτες: Drugs; Generic; Health policy; Pharmaceutical policy
@article{Balasopoulos2017-rx,
title = {Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions},
author = {T Balasopoulos and A Charonis and Kostas Athanasakis and John Kyriopoulos and Elpida Pavi},
year = {2017},
date = {2017-01-01},
urldate = {2017-01-01},
journal = {Health Policy},
volume = {121},
number = {3},
pages = {265--272},
address = {Ireland},
abstract = {OBJECTIVES: Since 2010, the memoranda of understanding were
implemented in Greece as a measure of fiscal adjustment. Public
pharmaceutical expenditure was one of the main focuses of this
implementation. Numerous policies, targeted on pharma spending,
reduced the pharmaceutical budget by 60.5%. Yet, generics'
penetration in Greece remained among the lowest among OECD
countries. This study aims to highlight the factors that affect
the perceptions of the population on generic drugs and to suggest
effective policy measures. METHODOLOGY: The empirical analysis is
based on a national cross-sectional survey that was conducted
through a sample of 2003 individuals, representative of the
general population. Two ordinal logistic regression models were
constructed in order to identify the determinants that affect the
respondents' beliefs on the safety and the effectiveness of
generic drugs. FINDINGS: The empirical findings presented a
positive and statistically significant correlation with income,
bill payment difficulties, safety and effectiveness of drugs,
prescription and dispensing preferences and the views toward
pharmaceutical companies. Also, age and trust toward medical
community have a positive and statistically significant
correlation with the perception on the safety of generic drugs.
Policy interventions are suggested on the bases of the empirical
results on 3 major categories; (a) information campaigns, (b)
incentives to doctors and pharmacists and (c) to strengthen the
bioequivalence control framework and the dissemination of
results.},
keywords = {Drugs; Generic; Health policy; Pharmaceutical policy},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVES: Since 2010, the memoranda of understanding were
implemented in Greece as a measure of fiscal adjustment. Public
pharmaceutical expenditure was one of the main focuses of this
implementation. Numerous policies, targeted on pharma spending,
reduced the pharmaceutical budget by 60.5%. Yet, generics'
penetration in Greece remained among the lowest among OECD
countries. This study aims to highlight the factors that affect
the perceptions of the population on generic drugs and to suggest
effective policy measures. METHODOLOGY: The empirical analysis is
based on a national cross-sectional survey that was conducted
through a sample of 2003 individuals, representative of the
general population. Two ordinal logistic regression models were
constructed in order to identify the determinants that affect the
respondents' beliefs on the safety and the effectiveness of
generic drugs. FINDINGS: The empirical findings presented a
positive and statistically significant correlation with income,
bill payment difficulties, safety and effectiveness of drugs,
prescription and dispensing preferences and the views toward
pharmaceutical companies. Also, age and trust toward medical
community have a positive and statistically significant
correlation with the perception on the safety of generic drugs.
Policy interventions are suggested on the bases of the empirical
results on 3 major categories; (a) information campaigns, (b)
incentives to doctors and pharmacists and (c) to strengthen the
bioequivalence control framework and the dissemination of
results.
implemented in Greece as a measure of fiscal adjustment. Public
pharmaceutical expenditure was one of the main focuses of this
implementation. Numerous policies, targeted on pharma spending,
reduced the pharmaceutical budget by 60.5%. Yet, generics'
penetration in Greece remained among the lowest among OECD
countries. This study aims to highlight the factors that affect
the perceptions of the population on generic drugs and to suggest
effective policy measures. METHODOLOGY: The empirical analysis is
based on a national cross-sectional survey that was conducted
through a sample of 2003 individuals, representative of the
general population. Two ordinal logistic regression models were
constructed in order to identify the determinants that affect the
respondents' beliefs on the safety and the effectiveness of
generic drugs. FINDINGS: The empirical findings presented a
positive and statistically significant correlation with income,
bill payment difficulties, safety and effectiveness of drugs,
prescription and dispensing preferences and the views toward
pharmaceutical companies. Also, age and trust toward medical
community have a positive and statistically significant
correlation with the perception on the safety of generic drugs.
Policy interventions are suggested on the bases of the empirical
results on 3 major categories; (a) information campaigns, (b)
incentives to doctors and pharmacists and (c) to strengthen the
bioequivalence control framework and the dissemination of
results.
2016
Konerding, Uwe; Bowen, Tom; Forte, Paul; Karampli, Eleftheria; Malmström, Tomi; Pavi, Elpida; Torkki, Paulus; Graessel, Elmar
Investigating burden of informal caregivers in England, Finland and Greece: an analysis with the short form of the Burden Scale for Family Caregivers (BSFC-s) Journal Article
In: Aging Ment Health, vol. 22, no. 2, pp. 280–287, 2016.
Abstract | BibTeX | Ετικέτες: Dementia; caregiver burden; comparison between European countries; cultural differences; informal caregivers
@article{Konerding2016-vh,
title = {Investigating burden of informal caregivers in England, Finland
and Greece: an analysis with the short form of the Burden Scale
for Family Caregivers (BSFC-s)},
author = {Uwe Konerding and Tom Bowen and Paul Forte and Eleftheria Karampli and Tomi Malmström and Elpida Pavi and Paulus Torkki and Elmar Graessel},
year = {2016},
date = {2016-10-01},
journal = {Aging Ment Health},
volume = {22},
number = {2},
pages = {280--287},
address = {England},
abstract = {OBJECTIVES: The burden of informal caregivers might show itself
in different ways in different cultures. Understanding these
differences is important for developing culture-specific measures
aimed at alleviating caregiver burden. Hitherto, no findings
regarding such cultural differences between different European
countries were available. In this paper, differences between
English, Finnish and Greek informal caregivers of people with
dementia are investigated. METHODS: A secondary analysis was
performed with data from 36 English, 42 Finnish and 46 Greek
caregivers obtained with the short form of the Burden Scale for
Family Caregivers (BSFC-s). The probabilities of endorsing the
BSFC-s items were investigated by computing a logit model with
items and countries as categorical factors. Statistically
significant deviation of data from this model was taken as
evidence for country-specific response patterns. RESULTS: The
two-factorial logit model explains the responses to the items
quite well (McFadden's pseudo-R-square: 0.77). There are,
however, also statistically significant deviations (p < 0.05).
English caregivers have a stronger tendency to endorse items
addressing impairments in individual well-being; Finnish
caregivers have a stronger tendency to endorse items addressing
the conflict between the demands resulting from care and demands
resulting from the remaining social life and Greek caregivers
have a stronger tendency to endorse items addressing impairments
in physical health. CONCLUSION: Caregiver burden shows itself
differently in English, Finnish and Greek caregivers.
Accordingly, measures for alleviating caregiver burden in these
three countries should address different aspects of the
caregivers' lives.},
keywords = {Dementia; caregiver burden; comparison between European countries; cultural differences; informal caregivers},
pubstate = {published},
tppubtype = {article}
}
OBJECTIVES: The burden of informal caregivers might show itself
in different ways in different cultures. Understanding these
differences is important for developing culture-specific measures
aimed at alleviating caregiver burden. Hitherto, no findings
regarding such cultural differences between different European
countries were available. In this paper, differences between
English, Finnish and Greek informal caregivers of people with
dementia are investigated. METHODS: A secondary analysis was
performed with data from 36 English, 42 Finnish and 46 Greek
caregivers obtained with the short form of the Burden Scale for
Family Caregivers (BSFC-s). The probabilities of endorsing the
BSFC-s items were investigated by computing a logit model with
items and countries as categorical factors. Statistically
significant deviation of data from this model was taken as
evidence for country-specific response patterns. RESULTS: The
two-factorial logit model explains the responses to the items
quite well (McFadden's pseudo-R-square: 0.77). There are,
however, also statistically significant deviations (p < 0.05).
English caregivers have a stronger tendency to endorse items
addressing impairments in individual well-being; Finnish
caregivers have a stronger tendency to endorse items addressing
the conflict between the demands resulting from care and demands
resulting from the remaining social life and Greek caregivers
have a stronger tendency to endorse items addressing impairments
in physical health. CONCLUSION: Caregiver burden shows itself
differently in English, Finnish and Greek caregivers.
Accordingly, measures for alleviating caregiver burden in these
three countries should address different aspects of the
caregivers' lives.
in different ways in different cultures. Understanding these
differences is important for developing culture-specific measures
aimed at alleviating caregiver burden. Hitherto, no findings
regarding such cultural differences between different European
countries were available. In this paper, differences between
English, Finnish and Greek informal caregivers of people with
dementia are investigated. METHODS: A secondary analysis was
performed with data from 36 English, 42 Finnish and 46 Greek
caregivers obtained with the short form of the Burden Scale for
Family Caregivers (BSFC-s). The probabilities of endorsing the
BSFC-s items were investigated by computing a logit model with
items and countries as categorical factors. Statistically
significant deviation of data from this model was taken as
evidence for country-specific response patterns. RESULTS: The
two-factorial logit model explains the responses to the items
quite well (McFadden's pseudo-R-square: 0.77). There are,
however, also statistically significant deviations (p < 0.05).
English caregivers have a stronger tendency to endorse items
addressing impairments in individual well-being; Finnish
caregivers have a stronger tendency to endorse items addressing
the conflict between the demands resulting from care and demands
resulting from the remaining social life and Greek caregivers
have a stronger tendency to endorse items addressing impairments
in physical health. CONCLUSION: Caregiver burden shows itself
differently in English, Finnish and Greek caregivers.
Accordingly, measures for alleviating caregiver burden in these
three countries should address different aspects of the
caregivers' lives.